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ABSTRACT 
Following its introduction to clinical use, noninvasive prenatal testing (NIPT) has 
dramatically altered the landscape of prenatal screening. Due to its high detection rate of 
trisomies 21, 18, and 13, along with sex chromosome aneuploidies, many patients are choosing 
NIPT over traditional screening and diagnostic methods. Previously, this testing was offered to 
women whose pregnancies were at an increased risk for aneuploidies. Now, guidelines from 
professional organizations recommend that NIPT should be included as a screening option for all 
pregnant women. Additionally, laboratories have started to expand NIPT to include 
microdeletions and microduplications, and are investigating the detection of monogenic 
disorders as well.  
With the rapid introduction of NIPT, surveying health care providers can help to 
determine how screening guidelines are being implemented in the clinical setting, an important 
aspect of two of the core public health functions: policy development and assurance. This project 
assessed obstetricians’ knowledge of NIPT, their readiness for offering NIPT to all women 
during pregnancy, and the expansion of NIPT testing options through an online survey conducted 
from February 3, 2017 to March 20, 2017. The survey was distributed to 4,770 ACOG members 
via their professional list serve and was completed by 238 participants. Results found that most 
participants demonstrated accurate knowledge of NIPT, but there was a discordance between 
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clinical practice and current guidelines about offering NIPT to the general obstetric population as 
45.72% indicted not offering NIPT to low-risk patients. Additionally, when asked about 
expanded NIPT options, 54.08% indicated that they were not confident in test interpretation and 
54.54% were not confident in their explanation of results to patients. This coincided with 
respondents expressing a preference for choosing what, if any, expanded testing should be 
offered to patients. Overall, participant confidence and comfort declined with expanded testing. 
Informational material and educational support regarding expanded NIPT testing should be 
developed for obstetricians.  
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1.0  INTRODUCTION  
Prenatal genetic testing is utilized by healthcare professionals for care of their patients 
throughout pregnancy. The purpose of prenatal testing is to screen for and diagnose medical 
conditions in the developing fetus. The identification of medical conditions prenatally can allow 
for medical management decision-making to occur prior to birth. This may include coordinating 
lifesaving surgery, giving anticipatory guidance to parents about what to expect of their child’s 
condition, or a discussion of pregnancy termination.  
Chromosome abnormalities, including aneuploidy, occur in approximately 0.65% of live 
born children and more than half of clinically recognized early pregnancy losses.1–3 Instances of 
aneuploidy are associated with increased maternal age. In the United States, women aged 35 and 
older at the time of delivery are considered to be of advanced maternal age and are at an 
increased risk of having a baby with a chromosome abnormaility.3,4  
Prenatal tests are classified as either screening or diagnostic tests. A screening test is 
designed to identify women whose pregnancies are at an increased risk for chromosome 
abnormalities or birth defects such as neural tube defects. Screening tests cannot confirm 
abnormalities. Such screening tests include imaging with ultrasonography and/or analysis of 
serum proteins and hormones in a multiple marker screen. A diagnostic test yields nearly 
definitive answers since it allows for genetic analysis of placental tissue or fetal cells present in 
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amniotic fluid.2 However, diagnostic tests are also associated with an increased risk for 
miscarriage.  
In 2011, the development and clinical availability of a new method of prenatal screening 
emerged: non-invasive prenatal testing (NIPT). NIPT is a screening test that is based on 
detecting cell free fetal DNA (cffDNA) in a maternal blood sample. The test has been promoted 
for its increased accuracy in detecting common fetal aneuploidies.5  Initially, NIPT was 
recommended for women considered to be at high-risk for aneuploidies. In 2016, the American 
College of Obstetricians and Gynecologists (ACOG) released a practice bulletin which indicated 
that all women, regardless of age, should be offered the option of screening or diagnostic testing 
for aneuploidies and NIPT was included as one of the screening options.6  
The uptake of NIPT has been rapid and is beginning to take the place of conventional 
screening methods. Within a year of introducing NIPT, one center experienced a 48.7% decrease 
in first trimester screening.57 In conjunction with the recent changes to practice recommendations 
by professional organizations, it is therefore important to examine healthcare providers’ 
knowledge, opinions, and practices surrounding NIPT.  
The purpose of this project was to survey currently practicing, US –based obstetricians of 
ACOG regarding their knowledge of NIPT, elicit their current clinical practices of presently 
available expanded NIPT testing, and assess readiness for future expansions of NIPT. Assessing 
these specific aims will help in identifying gaps in provider knowledge, differences in 
recommendations and practice, and how providers are planning to use expanded testing. 
Confirming providers’ knowledge ensures the accuracy of information that patients receive. As 
technological growth surrounding this test continues to evolve rapidly, and professional 
3 
organizations attempt to update their recommendations to include policies regarding new 
developments, it is imperative to know if providers can remain up-to-date. 
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2.0  LITERATURE REVIEW 
2.1 BACKGROUND 
2.1.1 Aneuploidy  
Aneuploidy is defined as an abnormal number of chromosomes in a cell, most often occurring by 
nondisjunction. Aneuploidy is estimated to occur at an incidence of 10-30% of all pregnancies 
and can result in miscarriage, stillbirth, and congenital anomalies.10   
The most common aneuploidies in liveborn children are the major trisomies, trisomy 21, 
trisomy 18, and trisomy 13, as well as sex chromosome aneuploidies: XXX, XXY, XYY, and 
45,X.3,11 According to the CDC, trisomy 21, more commonly known as Down syndrome, occurs 
in 1 in 691 livebirths in the United States.12 The incidences of trisomy 18 and 13 are 1 in 3,762 
and 1 in 7,906, respectively.12 Sex chromosome aneuploidy incidences are estimated to range 
between 1 in 400 and 1 in 1,000 in the general population.13 
One of the risk factors for aneuploidy is advanced maternal age. Numerous studies have 
modeled the predicted prevalence of aneuploidy as maternal age increases.4,14 Advanced 
maternal age (AMA) is defined as the age of 35 years at delivery. The age of 35 years or older 
has been used as a criterion to designate high-risk pregnancies that should be offered additional 
testing options for aneuploidy screening. Currently, advanced maternal age is not the only 
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criteria to indicate a high-risk pregnancy. Family history, abnormal ultrasound results, and 
positive prenatal screening results can also place women into a high-risk population for 
aneuploidy.15  
2.1.2  Prenatal Screening and Diagnosis of Genetic Conditions 
2.1.2.1 A Brief History of Prenatal Diagnosis and Screening 
Prenatal screening and diagnosis aim to strike a balance between accuracy of information 
gathered and corresponding risk involved. Traditionally, screening methods carry no risk to the 
pregnancy, but have lower accuracy. Conversely, diagnostic testing is exceptionally accurate, but 
confers a risk due to the nature of the procedures. As described by laboratories that provide 
NIPT, the promise of NIPT is superior screening accuracy compared to traditional screening 
methods without the risk associated with a diagnostic test.16–21 
There are currently two methods by which aneuploidy is diagnosed prenatally:  chorionic 
villus sampling and amniocentesis. These procedures allow for samples to be acquired and 
cultured for analysis. Karyotyping cultured cells is 97.5- 99.8% accurate.5,22,23 Other types of 
analyses including fluorescence in situ hybridization (FISH) and microarray are more than 99% 
accurate.24–26  
Amniocentesis was first performed in 1952 and by the mid-1970s was the standard 
procedure for obtaining fetal karyotypes.27 It is offered to women after 15 weeks gestation. The 
procedure allows access to the amniotic fluid, which contains fetal cells that have been shed. The 
fetal cells are then cultured for analysis. Amniocentesis has the added benefit of allowing for the 
measurement of alpha-fetoprotein (AFP) and acetylcholinesterase (AChE). Elevated levels can 
indicate birth defects such as abdominal wall defects and neural tube defects.2,27,28  
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Chorionic villus sampling (CVS) was clinically introduced in the 1970s and 1980s.27 It is 
offered to women during weeks 10-12 of gestation. The procedure involves obtaining a placental 
villi sample. The villi are typically genetically representative of the fetus since they both arise 
from the same totipotent stem cells.2,27,28  
Due to the methods by which samples are acquired, both procedures are considered 
invasive and are associated with an increased risk for miscarriage. Previous studies indicated a 
1% and a 1-2% risk of miscarriage for amniocentesis and CVS, respectively.28,29 A recent meta-
analysis concluded that miscarriage rates are lower than currently quoted to patients.11,12 The 
pooled risks were 0.11% for amniocentesis and 0.22% for CVS.32 In the past, CVS was also 
correlated with fetal limb anomalies.33 However, a large review showed no difference in limb 
anomalies between the general population and CVS when the procedure was performed between 
9-12 weeks gestation.34  
There are several prenatal screening methods available to women during pregnancy. 
These screening tests help to identify pregnancies that are at an increased risk for aneuploidy by 
modifying the mother’s age-related risk with personal information about her current pregnancy. 
Although all women, regardless of age, are at risk to have a child with aneuploidy, this risk 
increases with age.  
The first screening method used to identify pregnancies at increased risk for aneuploidy 
and other birth defects is ultrasonography, which is routinely performed throughout pregnancies 
to assess development and growth. Anatomic ultrasounds, typically offered to all women, are 
usually performed between 18-20 weeks gestation. These ultrasounds can identify physical 
anomalies, or markers, some of which are associated with aneuploidy. For example, common 
markers that are associated with Down syndrome include: heart defects, thickened nuchal fold, 
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shortened long bones, hyperechogenic bowel, echogenic intracardiac focus and pylectasis.35 
Each isolated marker has a likelihood ratio associated with it, with the likelihood ratio increasing 
when additional markers are present. Conversely, the absence of markers decreases the risk.36 
Ultrasounds are generally offered to all women, making it an important screening tool for the 
general population.35 The anatomic ultrasound alone detects 73% of Down syndrome cases, and 
has a 4% false positive rate.35,37 Other aneuploidies can be suspected based on ultrasound 
findings: cystic hygromas are associated with monosomy X, choroid plexus cysts and 
omphalocle with trisomy 18, and holoprosencephaly with trisomy 13.38,39  
Second trimester biochemical screening, also referred to as multiple marker screening, is 
traditionally performed between 16-20 weeks gestation. These tests combine maternal age, 
weight, race, diabetic status, pregnancy history, and gestational age along with the level of 
several biochemical markers to assess risk. The test is known as a multiple marker screening 
(MMS). Although the number of makers used is dependent on the lab, typically three (a triple 
screen) or four (a quad screen) are used, although a pentascreen is also available.40 The triple 
screen analyzes levels of maternal serum alpha-fetoprotein, unconjugated estriol, and human 
chorionic gonadotrophin. The quad screen incorporates inhibin A, as well.27 This screening can 
identify pregnancies with an increased risk of Down syndrome, trisomy 18, and open neural tube 
defects. The triple screen detects 70% and the quad screen detects 75% of Down syndrome. They 
have a false positive rate of 5%.35,41 Table 1 compares detection and false positive rates of the 
common trisomies across various screening methods. 
First trimester screening (FTS) is offered between 11-14 weeks gestation. It relies on a 
combination of maternal serum marker levels and a specific fetal measurement. The maternal 
serum markers are pregnancy associated plasma protein A (PAPP-A) and free beta human 
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chorionic gonadotrophin. The fetal measurement is an evaluation of thickness of the nuchal 
translucency, which is visualized by ultrasound during the first trimester. A thickened nuchal 
translucency is associated with fetal aneuploidy.42 In addition to Down syndrome, FTS has the 
added benefit of screening for trisomies 18, and in some cases trisomy 13, as well.43 The 
detection rate for each of these trisomies is 90%  with a 5% false positive rate.14,44 Notably, FTS 
does not specifically test for open neural tube defects.  
To further improve detection, a combination first and second trimester screening, known 
as an integrated screen has been developed. Integrated screening uses PAPP-A levels and NT 
thickness from the FTS and combines it with the second trimester quad screen. Only the 
combined result is disclosed to the patient. Integrated screening detects 85-87% of Down 
syndrome with a false positive rate of 0.8%-1.5%.41,43 The availability of integrated screening is 
often dependent on the healthcare institution. Due to the challenge of not disclosing FTS 
screening results to patients, alternatives to integrated screening are also available: sequential 
and contingent screening. Sequential screening takes a step-wise approach. Women with high-
risk FTS results are offered the additional second trimester screening, the results of which are 
incorporated into the FTS results. Contingent screening distinguishes between increased risk and 
high risk women by triaging with a first trimester screen. Women who are at an increased risk 
are initially offered screening while high risk women are  initially offered second trimester 
diagnostic testing.41,43,45  
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Table 1 Summary of Prenatal Screening Detection and False Positive Rates 
Screening Test 
for Common Trisomies 
Detection Rate False Positive Rate 
21 18 13 21 18 13 
Anatomic Ultrasound35,38,39  73% 80% 90-100%* 4% n/a n/a 
Multiple Marker Screen46–48 70-75% 60% n/a 5% 8% n/a 
First Trimester Screen46,47 90% 90% 90% 5% 5% 5% 
*When complete structural survey, including the heart, is completed39 
2.1.2.2 Non-Invasive Prenatal Testing (NIPT)  
NIPT is a screening test available after 10 weeks gestation. Traditionally, it was recommended 
for high-risk pregnancies, although it is now an option available to all women. NIPT utilizes 
cffDNA found in maternal blood samples. cffDNA are DNA fragments originating from the 
placenta. Like in CVS, placental tissue and fetal tissue differentiate from the same totipotent 
stems cells and therefore are thought to be representative of fetal tissue for the purposes of a 
screening test.  
In 1996, cell free DNA (cfDNA) unique to a patient’s cancer cells was identified in blood 
samples.49 In 1997, researchers took the detection of cfDNA further by looking for fetal cfDNA 
(cffDNA) in pregnant women. Researchers were able to extract DNA from plasma and serum 
samples and accurately detect the presence of Y chromosome signaling in the PCR samples of 24 
of the 30 male fetuses. Furthermore, none of the 13 female fetuses and the ten non-pregnant 
control women had a positive Y chromosome signaling.50 A year later, the same group showed 
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that fetal DNA can be detected in 10µL of maternal serum and plasma. The fetal fraction was 
reported to be 3.4-6.2% of the maternal sample in both early and late pregnancy.51 This work led 
to the utilization of cffDNA for prenatal screening.50,51 
After multiple validation studies were conducted, NIPT became clinically available in 
2011.52 A review of 16 studies from 1997-2012 evaluating the accuracy of NIPT to detect Down 
syndrome in high-risk women indicated an overall 99.3% detection rate for Down syndrome with 
a false positive rate of 0.16%. Detection and false positive rate were 97.4% and 0.15% for 
trisomy 18 and 78.9% and 0.41% for trisomy 13.53 Overall, these detection rates are increased 
compared other prenatal screening methods.  
 Given that the detection of Y chromosomes initiated NIPT, it is not surprising that NIPT 
also allows for screening of sex chromosome aneuploidy.  A review article discussing the testing 
of sex aneuploidies analyzed the combined detection rates of three previous studies: 89% for 
45,X, 82% for XXY, 87% for XXX, and 90% for XYY.54   
Given the high detection rate for aneuploidies in high-risk women, NIPT became a test 
offered to this population. More recently, detection rates have been investigated in low-risk 
women. Studies of clinical experience using NIPT as a screening method for the common 
trisomies in the general population show it to be clinically effective. A study published in 2013 
followed 288 patients, whose average age was 32.3 years, undergoing NIPT between July 2012 
and December 2012. Four of these patients had samples that failed quality control, but the 
remaining 284 were given results, all of which indicated low risk for trisomy. FTS results were 
available for 267 of these patients. One patient who had an abnormal FTS and low risk NIPT 
result underwent invasive testing which revealed the FTS to be a false positive result. One other 
patient whose NIPT result was low risk but FTS risk was one in five, underwent invasive testing 
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and was found to have a euploid fetus. Of note, this study was supported by Ariosa (Harmony), 
one of the laboratories currently offering NIPT.55 A meta-analysis determined that specifically in 
regard to the detection of Down syndrome, there was high sensitivity (0.993) and specificity 
(0.999) in pregnant women from the general population. Due to the limited number of trisomy 18 
and 13 cases in the dataset, their corresponding specificity and sensitivity could not be 
calculated.56   
There are a number laboratories offering NIPT testing in the United States. Table 2 
summarizes the sensitivity and specificity of the different tests and Table 3 indicates what 
microdeletion/duplications are available.  
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Table 2 Comparison of Sensitivity and Specificity Clinically Available NIPT Testing Options 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MaterniT21 
Plus18 Verifi
21,57,58 Panorama16,59 Harmony17,60 informaSeq19,61 QNatal Advanced20 
Aneuploidy  
Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec 
13 91.7% 99.7% 87.5% >99.9% >99.9% 100% 93.8% 99.98% 98.2% 99.9% 91.7% 99.7% 
18 >99.9% 99.6% 97.4% 99.6% >96.4% 100% 97.4% 99.98% 98.3% 99.9% >99.9% 99.6^ 
21 99.1% 99.9% >99.9% 99.8% 99.4% 100% 99.3% 99.96% 99.1% 99.9% 99.1% 99.9% 
XX 99.4% 99.4% 97.6% 99.2% >99.9% 100%   97.6% 99.2%   
XY 99.4% 99.4% 99.1% 98.9% >99.9% 100%   99.1% 98.9%   
Sex Aneuploidy 96.2% 99.7%   100% 100%     96.2% 99.7% 
Triploidy     >99.9% 100%       
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Table 3 Comparison of Clinically Available Expanded NIPT Testing Options 
 
 
 
 
 
 
 
 
 
 
 MaterniT21 Plus18 Verifi
21,57,58 Panorama16,59 Harmony17,60 informaSeq19,61 QNatal Advanced20 
Microdeletion 
options 
available Yes No Yes No Yes No Yes No Yes No Yes No 
22q (DiGeorge 
syndrome) •  •  •   •  • •  
15q (Pradar-
Willi/Angelman 
syndromes) •  •  •   •  • •  
11q (Jacobsen 
syndrome) •   •  •  •  • •  
8q (Langer-
Giedion 
syndrome) •   •  •  •  • •  
5p (Cri-du-chat 
syndrome) •  •  •   •  • •  
4p (Wolf-
Hirschhorn 
syndrome) •  •   •  •  • •  
1p36 deletion 
syndrome •  •  •   •  • •  
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Although NIPT has higher detection rates for the common trisomies when compared to 
other prenatal screening tests and can detect sex aneuploidies, the testing does have limitations. 
Maternal serum screening and amniocentesis can yield information about the risk for open neural 
tube defects, whereas NIPT cannot. Women who undergo NIPT, as opposed to other screening 
methods need to rely on maternal serum AFP screening and an anatomic ultrasound for detecting 
open neural tube defects.  
 NIPT currently detects the common trisomies and sex aneuploidies. Chromosome 
problems that would not be detected include balanced translocations, deletions, and duplications. 
However, some laboratories have started to include specific microdeletions/duplications as part 
of their NIPT tests. Currently, the only way to accurately assess chromosomes in their entirety is 
via diagnostic tests that result in karyotypes or microarrays.  
 As with any screening test, false positive results can occur due to the nature of the test. 
False positives can also be caused by vanishing twin, maternal malignancy, or mosaicism of the 
placenta, fetus, or mother.50,62–64The false positive rate is not available for each lab. However, 
Harmony reports <0.1% for Trisomies 13, 18, and 21; Panorama reports <0.1% for Trisomy 18 
and 0% for Trisomies 21 and 13; Verifi reports an observed false positive rate of 0.12%.16,17,21,57–
60 
 Inconclusive, no-call, or test failure results can occur with NIPT and can be due to the 
following factors: maternal obesity, low fetal fraction, low sample volume, and maternal 
malignancy.62–64  Although the rate of test failure is not readily available for each lab, the 
following rates have been reported: Panorama 3.8%, Harmony 3%, MaterniT21 1.3%, and Verifi 
0.1%.16–18,21,57–60 
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 The terminology in which results are disclosed to patients and providers varies across 
laboratories. For example, Sequenom reports indicate “positive” or “negative”, Verifi reports 
indicate “aneuploidy detected” or “no aneuploidy detected”, and Panorama reports indicate “high 
risk” or “low risk”.  This may create differences in understanding the results of the test and make 
result interpretation more difficult.  
2.1.2.3 Effects of NIPT 
The introduction of NIPT has had a significant effect on prenatal testing.  Shortly before NIPT 
became available in 2011, a 2010 survey of 62 obstetric healthcare providers participating in a 
continuing education course inquired about perceived impact of cffDNA testing. The survey 
indicated that only 29% of surveyed practitioners believed they would be offering the testing 
within the next five years and 52% indicated they were ambivalent about cffDNA.65 A 2013 
study which surveyed 278 maternal-fetal medicine specialists indicated that more than 90% of 
maternal fetal medicine specialists had adopted NIPT into their practice, showing a rapid uptake 
in testing.7 Wallerstein et al.  conducted a nine-month prospective study in 2013, as they 
integrated NIPT into their screening model by following the screening decisions of 163 women 
of advance maternal age. When given the option, patients indicate a preference for NIPT over 
integrated screening, invasive testing, and no screening.8 This holds true with the high-risk 
population as well. A 51-month study evaluated of the uptake of NIPT and its effect on the use 
of other screening methods as it was implemented within a large academic referral center. It 
showed a 48.7% decrease in FTS, the previously preferred testing method at that center, after the 
first year NIPT was available, indicating that NIPT was the preferred test by this high-risk 
population.9 In terms of provider preference, a 2015 questionnaire completed by 240 obstetric 
healthcare providers showed a majority (72%) were in favor of replacing first trimester 
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combined screening  with NIPT, although 43% of respondents would like to maintain NT 
measurements.66  
 It appears that the higher detection rates are one of the main reasons for NIPT becoming 
more utilized than other screening tests. However, there has also been a decrease in diagnostic 
testing since the introduction of NIPT.67 Diagnostic testing rates were already on the decline and 
predicted to decrease further with NIPT.67 In the study conducted by Wallerstein et al., the center 
saw amniocentesis procedures decrease by 31%  due to patients choosing NIPT over invasive 
testing.8 The availability of NIPT as early as 10 weeks gestation is also hypothesized to partially 
explain the decrease in diagnostic tests which are offered during limited windows, later in 
pregnancy.67 There is concern that the reduction in diagnostic testing will result in these 
procedures having a higher risk of complications.67 With less women electing to have diagnostic 
testing, there is less opportunity to train new physicians. Although diagnostic procedures are 
invasive and inherently have a risk for complications associated with them, the rate of test failure 
and miscarriage decreases as the experience and skill of the physician increase.67  
2.1.3 Guidelines, Position Statements, and Recommendations  
As new technology develops, professional societies utilize position statements and practice 
guidelines to ensure that healthcare practitioners employ advances properly and apply best 
practices. The introduction of NIPT is no exception. The professional societies that represent 
genetic counselors, clinical and laboratory geneticists, and obstetricians and gynecologists have 
contributed recommendations regarding NIPT since its clinical availability in 2011.  
In 2012, the National Society of Genetic Counselors (NSGC) published a practice 
guideline on the topic of prenatal screening and diagnostic testing options for chromosome 
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aneuploidy. It stated the importance of being aware of newer testing options like NIPT in order 
to provide patients with reliable and accurate information. The high detection rates for trisomy 
21, 18, and 13 were noted. The guideline recommended confirmatory diagnostic testing for 
positive NIPT results and that additional serum screening should not be performed in addition to 
NIPT. 68 Shortly thereafter in 2013, NSGC released a position statement regarding NIPT.15 The 
statement highlighted NIPT as a screening test, and reiterated that it should not be considered 
diagnostic. NSGC supported NIPT as a first-tier aneuploidy screening for high-risk populations, 
but not low-risk populations. These high-risk populations included women who had positive 
maternal serum screens, a family history of aneuploidies, abnormal ultrasound findings, or were 
of advanced maternal age. NSGC did not support the use of NIPT to test for single gene 
disorders or aneuploidies other than trisomies 21, 18, and 13, and monosomy X. In conclusion, 
the statement acknowledged the rapid developments being made and that positions would be 
likely to shift with time.15 In October 2016, NSGC released a position statement supporting 
NIPT as an option for patients, while acknowledging that due to a variety of factors it may not be 
the most appropriate test for every patient. The statement reiterated that diagnostic testing should 
be offered to those whose results indicate an increased risk.69 
In 2015, the American College of Obstetricians and Gynecologist (ACOG) released a 
committee opinion from their Committee on Genetics.70 They stated that conventional screening 
methods remain the most appropriate as a first-tier screening method for the general population 
due to cost effectiveness. It also noted that simultaneous testing of multiple screening methods 
was not cost effective and was not recommended. If ultrasound indicates a structural 
abnormality, diagnostic testing should be offered instead of NIPT. Patients should be informed 
of the limitations of NIPT, including inability to assess neural tube or ventral wall defects, and 
18 
that negative results do not ensure an unaffected pregnancy. The opinion also stated that 
although patients have many options for prenatal screening and diagnosis, they are all optional 
and can be declined.70 
However, in 2016, ACOG released an updated Practice Bulletin stating that all women 
should be offered the option of screening and diagnostic testing, including NIPT. The bulletin 
discussed that testing chosen should be appropriate based on the concerns, needs, and values of 
the patients, while also acknowledging that not all testing is available in each center. Regarding 
microdeletions, diagnostic testing with microarray was recommended as cffDNA for 
microdeletions had not yet been clinically validated.6  
In 2016 an updated position statement was released by American College of Medical 
Genetics and Genomics (ACMG). In a shift from previous guidelines, ACMG recommended that 
all pregnant women should be informed that NIPT is the most sensitive screening option for 
common trisomies. It also recommended that all women be informed of the ability to expand 
testing to sex chromosome aneuploidies, but that providers should deter patients from utilizing 
NIPT for the sole purpose of sex identification. It did not recommend genome-wide exploration 
of copy number variants, and stated that diagnostic testing should be recommended if patients 
seek that level of information. ACMG also made recommendations to laboratories offering 
testing, calling for clearly stated detection rates, as well as both positive and negative predictive 
values. They also recommended that laboratories include fetal fraction on all results and specify 
the reason(s) for inconclusive results. Furthermore, the statement indicates that if an inconclusive 
result is given, then a repeat blood draw is not appropriate and the patient should be offer 
diagnostic testing.71 
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2.1.4 The Future is Now: Expanding Noninvasive Prenatal Testing and Diagnosis 
Although the introduction and subsequent uptake of NIPT has been rapid, the testing options 
available with NIPT are continuing to evolve.  In 2013, laboratories started to offer 
microdeletions and microduplications as an add-on possibility to NIPT. Table 3 indicates eight 
disorders caused by such genetic changes that are now being offered by NIPT laboratories. Of 
the six US based laboratories shown, two offer testing for all the microdeletions/duplication, 
three offer some combinations, and one does not offer microdeletion/duplication testing. 
 As the technology is developed, it is important to investigate patient preference for NIPT 
microdeletions/duplications testing. A study aimed at assessing this described six conditions 
caused by microdeletions/duplications, along with their penetrance, and then asked 124 women if 
they would choose NIPT, an invasive procedure, or no testing at all for the conditions. 
Participants indicated higher rates of testing, both invasive and noninvasive, as the penetrance of 
the condition increased. Overall, more than half of participants made distinctions between the 
conditions which affected their testing choices; 28% would choose NIPT for all the conditions, 
and 8% would choose invasive testing for all the conditions. However, 11% indicated that they 
would not like either testing.72 Although interest in testing was high, it was not universal. This 
study highlighted the need for a discussion between patients and providers regarding testing 
options, and to ensure expanding NIPT aligns with patient views and preferences.  
The lynchpin of expanding NIPT to include microdeletion/duplication testing is 
determining whether such testing can yield accurate results. A study funded by investors of 
Natera (Panorama) evaluated the performance of SNP-based NIPT for 
microdeletions/duplications. The study utilized 358 plasma samples from pregnant women and 
111 artificial plasma mixtures for a total of 469 test samples. The resulting detection rates were 
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97.8% for 22q11.2 deletion and 100% for Angelman, Pradar-Willi, 1p36 deletion, and cri-du-
chat. False positives occurred only in 22q11.2 deletion syndrome and cri-du-chat at a rate of 
0.76% and 0.24%, respectively.73 The study also called for the consideration of 
microdeletion/duplication testing for the general obstetric population as they collectively occur 
in more than 1% of all pregnancies.73 Conversely, a retrospective cohort study of clinical NIPT 
use in a MFM practice from March 2013 to July 2015 had 43 cases had abnormal microdeletion 
results reported using expanded screening. The condition detected were: DiGeorge, Angelman, 
and Cri-du-chat. Of these, 17 had non-reportable results and 9 were positive.  Confirmatory 
microarray was elected by seven of the nine microdeletion positive cases, and all were found to 
be false-positives, giving the test a positive predictive value of 0%.74   
In addition to concerns related to accuracy, provider awareness and knowledge of 
expanded testing, as well as willingness to utilize the testing are important considerations. A 
survey conducted between September 2014 and February 2015 of 85 obstetricians revealed that 
25% were unaware of expanded testing options and only 14% had ordered an expanded NIPT 
test. A majority (91%) expressed a need for more information specifically tailored to 
practitioners.75 
In addition to microdeletions/duplications, some laboratories have moved beyond 
common trisomies and sex aneuploidies. For example, Verifi21,57,58 optionally tests for trisomy 9 
and trisomy 16, and MaterniT21 Plus18 includes trisomy 16 and trisomy 22. The concept of 
genome-wide analysis for all aneuploidies has been investigated. However, the clinical utility of 
reporting all aneuploidies is debatable due to false-positive results leading to unnecessary 
invasive testing.76,77 
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As the sensitivity and specificity of NIPT increases, it is thought that NIPT could move 
from a screening test to a diagnostic test. A cost-effective analysis of using NIPT as a diagnostic 
test (NIPT Dx) was conducted. Using a sensitivity and specificity of 0.99 to diagnose Down 
syndrome, without confirmatory testing, the study found that more infants with Down syndrome 
would be born. In addition, a higher rate of elective terminations of fetuses not affected with 
Down syndrome would occur without confirmatory testing.78  
The development of monogenic disorder testing via NIPT has been slow in comparison to 
microdeletion/duplication testing. It has been speculated that developing tests for a disease, or 
even on a patient-specific basis is not a high-throughput model, limiting impetus for commercial 
development.79,80 A UK-based article argued that when discussing monogenic disorders, the test 
shifts from screening to diagnostic (NIPD) in high-risk pregnancies since there is either a known 
family history or ultrasound indications. The technical complexity of the testing depends on the 
inheritance pattern of the condition. For example, testing for a paternally inherited autosomal 
dominant condition would be simpler compared to X-linked or autosomal recessive conditions.81 
Technical challenges of such testing include the size of cffDNA, which is typically shorter than 
maternal cfDNA, and fetal fraction. The ideal testing methodology would involve separating the 
cffDNA in a reliable, cost-effective manner, or use of a paternal genotype to compare to 
maternal plasma.64,80 An ethical concern raised by NIPD is the routinization of such testing 
correspondingly decreasing informed choice for patients.82 However, NIPD would not be 
appropriate for every situation. Invasive testing would still be necessary for non-singleton 
pregnancies to determine if one or more fetuses are affected.80 
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2.1.5 Provider Attitudes, Knowledge, and Education  
The field of prenatal screening and diagnosis is ever evolving and rapidly changing, presenting a 
unique challenge to healthcare professionals who provide this information to their patients 
Understanding how these providers have learned about and reacted to the uptake of NIPT is 
therefore an important topic to investigate. As the testing became available, an article published 
in Obstetrics & Gynecology called for caution, citing patients and healthcare providers, including 
geneticists, limited understanding of the test’s features and results interpretation. The need for 
education was underscored as essential, especially as the testing would likely become more  
complex.83  
Genetic Counselors 
A 2013 study conducted a thorough 67-question survey of 236 genetic counselors 
regarding their experiences with NIPT. A clear majority of counselors (96.1%) indicated they 
felt knowledgeable about cffDNA, were confident in offering testing to patients (94.2%), and 
were confident in their ability to explain subsequent results (93.2%). Respondents could provide 
additional comments as open text in the survey. Of the 72 who chose to use the open response, 
12.5% expressed concern about obstetrician impact on testing. The main themes that were 
expressed were that obstetricians were not knowledgeable about NIPT, that obstetricians took the 
testing too lightly, and that patients relied on obstetricians recommendations.84  
A 2015 survey of 113 genetic counselors assessed NIPT practice, counselor learning 
methods, and readiness for expanded testing options.85 Ninety five percent of genetic counselors 
agreed or strongly agreed that they were familiar with NIPT. The most common methods by 
which genetic counselors learned about NIPT were discussion with peers, literature review, 
discussion with laboratory representatives, and conferences. Regarding offering 
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microdeletion/duplication testing to patients, 45% did not offer such testing, 20% offered it to 
high-risk pregnancies only, and 16% offered it to all patients. When asked about the possibility 
of testing for monogenic disorders via NIPT, 32% approved, 21% disapproved, and 47% were 
neutral.85 Another survey of genetic counselors conducted in the same year found that 
participants were split on the idea of universal NIPT testing, with 47% being in favor. Those in 
opposition to universal screening expressed concern over knowledge of NIPT, specifically citing 
lack of provider understanding, the need for provider education, and the lack of patient 
understanding.86   
Nurses and Nurse-midwives  
An article published in Nursing Outlook acknowledged that trends in prenatal genetic 
testing are expected to affect nursing practice, education, research, and policy making. The 
article reviewed a variety of genetic tests relevant to prenatal care including preconception 
screening, carrier screening, conventional screening methods, and diagnostic testing with 
karyotyping and microarray. The newer developments discussed in this article included NIPT for 
fetal aneuploidies and whole genome testing. The article called for expanding genetic/genomic 
knowledge, suggesting that nurses take advantage of the resources provided by the American 
Nurses Association and that patient teaching material be created and maintained by ACNM. In 
addition, inclusion of genetics/genomics content in undergraduate and graduate training 
programs and continuing education activities regarding genetic testing would be essential in 
keeping nurses up to date.87 
Obstetricians and Maternal-Fetal Medicine  
A 2013 study surveyed 101 obstetricians after NIPT had been clinically available for a 
year. A clear majority (88%) of these providers felt that aneuploidy testing should be offered to 
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all women. At the time, the most common screening methods they used were second trimester 
ultrasounds (76%) and second trimester serum screening (58%). Regarding NIPT, 32% were 
currently using it in their practices at the time of response and 22% indicated they were familiar 
with the technology, but had not yet ordered the test. Notably, only 12% felt aneuploidy 
screening should be offered to a high-risk population only, meaning the disagreed with the 
professional guideline recommendations at that time. Overall, the need for further education was 
clear if NIPT were to continue on to be widely adopted.88  
A study published in Prenatal Diagnosis surveyed ACOG Fellows between March and 
August 2012 about their opinions of NIPT. 89 Respondents were asked to assume that NIPT was 
accurate when considering different testing scenarios. Assuming acceptable accuracy, nearly all 
(97.5%) felt it should be used for all aneuploidies, and 90.4% believed it should be used for 
severe early-onset Mendelian disorders. However, of concern to the authors, nearly 50% of 
participants indicated that a Down syndrome test with a detection rate of 98% and a false 
positive rate of 0.2% would be an acceptable replacement of invasive testing, even though that 
would result an estimated one in six false positive NIPT results in a high-risk population.89 
When 116 maternal-fetal medicine fellows were surveyed in 2016, more than 75% 
indicated being comfortable with ordering NIPT, but 82% preferred that patients discuss testing 
options with providers or genetic counselors. Questions regarding the respondents’ education on 
NIPT found that formal educational activities (69%), review of literature (67.3%), and discussion 
with peers (64.6%) as the most common methods of learning about the test. Six questions 
evaluated participants’ knowledge and the results revealed that 34.8% correctly answered all six 
questions, 30.4% correctly answered five of six and the remaining 34.8% correctly answered 
four or less. Overall, participants’ responses indicated knowledge of trisomies in NIPT, but 
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accuracy decreased for questions about twin pregnancies and monosomy X screening. The 
authors of this study recommended that formal genomic education programs be implemented in 
MFM fellowships as NIPT advances continue to be made.90  
A 2016 study surveyed 258 general obstetrics-gynecologists and maternal-fetal medicine 
subspecialists regarding education of NIPT, practice patterns, and barriers.  The most common 
educational sources were publications from professional organizations, peer-reviewed journals, 
and online review articles for medical professionals. These were closely followed by continuing 
education courses.91  
2.2 PURPOSE OF THIS STUDY 
The addition of NIPT as a prenatal screening tool has changed how patients and providers seek 
information about pregnancies. Patients’ desire for NIPT over traditional screening methods is 
increasing and, as such, more providers are offering the screening. Additionally, as NIPT 
research has expanded from high-risk populations to the general obstetric population, healthcare 
provider guidelines have been adapted accordingly. Recent changes to professional guidelines 
and recommendation now include NIPT as a screening option for all women during their 
pregnancy. However, the scope of NIPT continues to broaden as testing companies introduce 
expanded testing. Given the dramatic impact of NIPT, it is important to assess providers offering 
the testing in its current form and understand their preparedness for its expansion. Knowing this 
information can identify areas where knowledge or comfort is lacking, be beneficial to 
professional organizations as they continue to update their guidelines and recommendations, and 
ensure the quality of patient care. Since a variety of healthcare providers are involved with 
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offering NIPT to patients, many specialty areas will need to be assessed. Previously, members of 
the NSGC were surveyed to elicit information from the genetic counseling community. This 
project continued exploring provider knowledge and comfort of NIPT by seeking the responses 
of obstetricians who are members of ACOG. The importance of this project is in the addition of 
another specialty’s relationship with NIPT.  
2.3 SPECIFIC AIMS 
Aim 1: To assess obstetricians’ knowledge of NIPT.  
 
Aim 2: To assess readiness of providers for the expansion of NIPT to all pregnancies, and the 
expansion of NIPT testing options in the future.  
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3.0  MANUSCRIPT  
3.1 INTRODUCTION 
Prenatal genetic testing is utilized by healthcare professionals in the care of their patients 
throughout pregnancy. The purpose of prenatal testing is to screen for and diagnose medical 
conditions such as aneuploidy. NIPT is a screening test that detects cell free fetal DNA (cffDNA) 
in a maternal blood sample and has been promoted for its increased accuracy in detecting 
common fetal aneuploidies: trisomy 21, trisomy 18, trisomy 13, and sex aneuploidies.5 Although 
sensitivity varies with specific laboratories, NIPT detects more than 99% of trisomy 21, 96-99% 
of trisomy 18, 91-99% of trisomy 13, and 96-100% of sex aneuploidy.17–21,57,58,60,61 It is these high 
detection rates which have led to its quick adoption in clinical practice.  
The uptake of NIPT has been rapid. In a 2011 survey, only 29% of obstetric providers 
believed they would be offering NIPT in the next five years, but a 2013 survey of maternal-fetal 
medicine specialists revealed a staggering 90% had adopted NIPT into their clinical practice.7,65 
As more providers make NIPT available, the use of conventional screening methods is declining. 
Within a year of introducing NIPT, one center experienced a 48.7% decrease in first trimester 
screenings.57 Although the use of invasive testing had been declining since the introduction of 
first trimester screening, the rate increased with the introduction of NIPT.67 A previous study 
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found a 31% decrease in amniocentesis that was attributed to patients choosing NIPT over 
invasive testing.8,67 
Previously NIPT, has traditionally been recommended only for women who were at an 
increased risk for aneuploidies, given that the early NIPT validation studies used high-risk 
populations. Therefore, the clinical validity of NIPT for the general obstetric population had not 
been shown.68,70 However, studies evaluating the sensitivity and specificity of NIPT in general 
obstetric populations showed it to be highly accurate in large populations of low-risk 
women.56,92,93  
High-risk patients are identified by a variety of means, including advanced maternal age, 
abnormal ultrasound findings, and a history of aneuploidy in previous pregnancies. However, in 
2016, many organization changed their policies regarding the appropriate testing population for 
NIPT. The American College of Obstetricians and Gynecologists (ACOG), American College of 
Medical Genetics (ACMG), and National Society of Genetic Counselors (NSGC) recommended 
that NIPT should be offered to all women.6,69,71 
Since its inception, NIPT has evolved to test for conditions other than common 
aneuploidies. Although each laboratory offering NIPT routinely tests for the trisomies 21, 18, 13, 
and sex aneuploidies, some have begun to offer testing for other aneuploidies, as well as select 
microdeletions and microduplications. The use of this expanded NIPT testing is currently not 
recommended by professional organizations.6,69,71 Additionally, research is underway to detect 
monogenic disorders through NIPT. For example, methods to identify thalassemia, a common 
hemoglobin disorder, via NIPT are being done by exploring the detection of paternally inherited 
mutations, maternally inherited mutation, and mutations known in both parents.94  
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As NIPT testing became available, studies have explored providers’ attitudes, knowledge 
and education. A 2013 article published in Obstetrics & Gynecology called for caution, citing 
patients and healthcare providers, including geneticists, limited understanding of the test’s 
features and results interpretation. Education was underscored as essential, especially as the 
testing would likely become more  complex.83 A 2015 survey of genetic counselors identified 
concerns that obstetricians were not knowledgeable about NIPT, that obstetricians took the 
testing too lightly, and that patients relied on obstetricians recommendations.84 Maternal-fetal 
medicine fellow surveyed in 2016 accurately answered questions regarding trisomies in NIPT 
but received lower scores on questions of twin pregnancies and monosomy X screening. 
Additionally, while many these fellows felt comfortable ordering NIPT, most preferred that 
patients discussed testing options with other providers, such as genetic counselors.90  The current 
body of research on these topics should continue to be developed as providers have more 
experience with NIPT, as NIPT changes and expands, and as more providers become part of the 
NIPT process.  
The purpose of this project was to survey members of ACOG regarding their knowledge 
of NIPT, elicit their current clinical practices regarding presently available expanded NIPT 
testing, and assess readiness for future expansions of NIPT. Assessing these specific aims will 
identify gaps in provider knowledge, differences in recommendations and practices, and how 
providers are planning to use expanded testing. Assessing providers’ knowledge ensures the 
accuracy of information that patients receive, and helps recognize potential areas for 
improvement. As technological growth surrounding this test continues to evolve rapidly and 
professional organizations attempt to update their recommendations to include policies regarding 
new developments, it is imperative to know if providers can remain up-to-date. 
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3.2 MATERIALS & METHODS  
3.2.1 Participants 
The participant population consisted of American Congress of Obstetricians and Gynecologist 
(ACOG) members. A cover letter along with an anonymous electronic link were distributed via 
email to a randomized list of 4770 currently practicing, US-based obstetricians who were ACOG 
members in February 2017. Of these, 1783 members opened the email, 301 clicked on the survey 
link, 289 began the survey, and 238 completed the survey. The survey was closed in March 
2017. A copy of the cover letter and survey are attached in Appendix B.  
3.2.2 Instrumentation and Procedures 
This study and survey (ID: PRO16100624) was approved by the Institutional Review Board of 
the University of Pittsburgh (Appendix A). The survey was created electronically in Qualtrics by 
Kerrianne Morrow, MS for a previous study that examined genetic counselors’ knowledge and 
opinions of NIPT.85 The survey contains 34 questions and was originally designed to elicit 
information from a variety NIPT providers: genetic counselors, obstetricians, and midwives. This 
survey was previously distributed to genetic counselors in 2016.85 For accurate comparisons 
across providers, the same survey was distributed to obstetricians. The survey contains both 
multiple choice and open-ended response options. The questions were developed to evaluate 
three areas: (1) assessing provider knowledge of NIPT and for what populations they ordered the 
test, (2) explore provider opinions and comfort with current and future NIPT testing, including 
expanded testing options of microdeletion, microduplication and monogenic disorders panels, 
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and (3) participant demographics. The survey did not elicit identifying information. It was 
reviewed by healthcare professionals representing a variety of disciplines including prenatal 
genetics, genetic counseling, obstetrics/gynecology, and an NIPT researcher.   
3.2.3 Data Analysis 
The data collected from the survey was analyzed using descriptive statistics. Participants were 
not required to answer all questions; therefore analysis was conducted individually for each 
question regardless of total respondent pool. All figures illustrating participant responses were 
created in Qualtrics. 
3.3 RESULTS  
3.3.1 Participants  
An invitation to participate was sent to 4,770 ACOG members, 1,783 members opened the email, 
301 clicked on the survey link, and a total of 289 participants began the survey. Of these, 238 
participants completed the survey (82.4%). The overall response rate was 4.98% (238/4,770). All 
the participants surveyed identified their specialty as Obstetrics and Gynecology. Most 
participants (90.72%) reported no subspecialty. Of the 22 participants that indicated a 
subspecialty, 50% (11) indicated Maternal Fetal Medicine, making it the most commonly 
reported subspecialty. Participants were asked to indicate how long they have been practicing in 
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the field. A majority (62.18%) of participants have been in practice for more than 10 years. This 
demographic information is summarized in Table 4. 
Table 4 Participant Demographics 
 Total (n=238) 
 n % 
Sub-specialty   
Yes 22 9.28% 
Maternal Fetal Medicine 11 50% 
Other 11 50% 
No 215 90.71% 
No Response 1 0.42% 
Primary Work Setting   
Academic  36 15.13% 
Private Practice  160 67.23% 
Hospital Based 41 17.42% 
Lab 1 0.42% 
Number of Years in Practice   
0-2 3 1.26% 
2-5 35 14.71% 
5-10 52 21.85% 
10+ 148 62.18 
 
3.3.2 Knowledge of NIPT  
Initial survey questions aimed to assess the participants’ current knowledge of NIPT. Participants 
were asked to what extent they agree or disagree with the statement: “I am familiar with 
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published NIPT clinical data.” Most answered positively about the statement with 64.71% 
indicating they agreed and 20.59% indicating they strongly agreed. Only 5.04% indicated they 
disagreed while 2.94% indicated they strongly disagreed, with 6.72% indicating they neither 
agreed nor disagreed (Figure 1).  
 
 
Figure 1 Participant Knowledge of Published NIPT Clinical Data 
  
Participants were asked to select all methods through which they learned about NIPT. 
Participants who indicated that they had not learned about NIPT were forwarded to the 
demographics section of the survey and not asked to respond to the remaining survey questions. 
There were two (0.84%) participants in this survey who indicated that they had not learned about 
NIPT.  
More than half of participants indicated that they learned about NIPT through discussion 
with peers (n=156, 65.55%) and literature review (n=124, 52.1%). This was followed closely by 
discussion with laboratory representatives (n=107, 44.96%) and continuing education courses 
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(n=101, 42.44%). Around a quarter of participants’ NIPT education occurred through online 
research (n=65, 27.31%), conferences (n=63, 26.47%), and formal education (n=63, 26.05%). 
Only 13.03% indicated laboratory company advertisements as a method of learning about NIPT. 
Fourteen (5.88%) participants indicated other means of educations. Figure 2 depicts the spread of 
educational methods from most to least used. In an available open-ended text response, 
participants had the opportunity to expand their answers. These responses included educational 
opportunities through their hospital, department meetings, genetic counselors, testing company 
sponsored dinners, and Maternal-Fetal Medicine consultations and presentations.  
 
Figure 2 NIPT Education Methods 
 
 The final question regarding provider knowledge was the gestational age at which NIPT 
could be performed. The clear majority of participants (94.89%) correctly answered that the test 
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could be conducted as early as 10 weeks gestation. Ten (4.26%) participants indicated the test 
could be done anytime and two (0.85%) indicated as early as 15 weeks.  
3.3.3 Current Clinical Practices  
The remainder of the survey involved questions pertaining to the participants current practice 
utilizing NIPT. Nearly all participants (n=230, 97.46%) indicated that they offered NIPT to high-
risk pregnancies. Six (2.54%) participants indicated that they did not. Of these six, three 
expanded on their answer. Their responses included referring patients to a Maternal-Fetal 
Medicine specialist and/or a genetic counselor who then offers testing. Most participants (n=179, 
77.83%) indicated that they offered or referred for NIPT for 90-100% of their high-risk patients. 
Figure 3 depicts the percentages of high-risk patients to whom participants offer NIPT.  
 
 
Figure 3 Percentage of Patients Offered/Referred NIPT who are at High-Risk for Aneuploidy 
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Figure 4 Percentage of Patients Offered/Referred NIPT who are at Low-Risk for Aneuploidy 
 
 When asked about pregnancies at low-risk for aneuploidy, participants were more 
divided, with 44.92% (n=106) offering NIPT and 55.08% (n=130) indicating that offering NIPT 
was not part of their practice. Following up with respondents who were not currently offering 
NIPT to the low-risk population, most (n=116, 89.92%) stated that they did not plan to change 
this practice within the next 12 months. However, 13 participants indicated that they would begin 
offering NIPT to low-risk pregnancies within the same timeframe.  Of the 106 participants who 
currently offer NIPT to low-risk patients, a majority (n=67, 63.21%) offer NIPT to 90-100% of 
this patient population. The remaining results are shown in Figure 4.   
 Participants were asked about perceived advantages and limitations of NIPT compared to 
other screening methods. The greatest advantages were patient acceptance (88.51%, n=208), 
availability during gestational age (86.70%, n=202), detection rate (81.28%, n=191), and 
associated risk to pregnancy (80.49%, n=165). The greatest limitation was coverage by insurance 
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companies (50.89%, n=114). Figure 5 shows respondents’ answers to this question in greater 
detail. Other limitations mentioned by participants in open-ended responses included sex 
selection, inability to do NIPT in house and having to refer patients outside to genetics, and the 
potential to detect abnormalities in the mother rather than the fetus without guidance on how to 
counsel the patient.  
 
 
Figure 5 Participant Indications of Advantages and Limitations of NIPT 
 
Participants were asked to indicate all methods by which information about NIPT for 
aneuploidy is conveyed to the patient prior to testing.  The most common method was a 
discussion between the patient and the participant about NIPT (n=200, 84.75%). The second 
most common method was an information handout that patients read (n=85, 36.02%). Less often, 
patients speak to a genetic counselor either face-to-face (n=67, 28.39%) or through telemedicine 
38 
(n=13, 5.51%).  Some patients spoke to a healthcare provider other than a genetic counselor 
either in the same office (n=41, 17.37%) or outside of the participant’s office (n=26, 11.02%).  
Regarding interpreting patient NIPT results, most participants favorably viewed their 
ability, with 40.6% indicating very confident, 32.05% mostly confident, and 23.50% confident. 
A similar trend is seen for explaining NIPT results to patients, as 44.26% indicated they were 
very comfortable, 30.64% mostly comfortable, and 20.85% comfortable.  
Following abnormal NIPT results, most (86.44%) participants indicated they would offer 
invasive diagnostic testing, while a minority (4.24%) would not offer such testing. However, 22 
(9.32%) participants indicated that their decision to offer diagnostic testing depends on the 
situation. In the open-ended response section, eight of eleven indicated that they would refer to 
Maternal-Fetal Medicine, who would discuss invasive diagnostic testing. Other situations 
mentioned were the willingness of the patients to risk miscarriage, gestational age, ultrasound 
findings, and if the patient is requesting pregnancy termination based on their NIPT results.  
Participants were asked at what point in the NIPT ordering process they would find 
access to a genetic counselor helpful. The most common points were before offering NIPT 
(39.4%) and after results were returned and were abnormal (41.53%). Some participants (16.1%) 
indicated that access to a genetic counselor would be helpful only when the results were 
abnormal, while a few (2.97%) indicated that they did not offer genetic counseling to patients.  
3.3.4 Expanded NIPT Testing   
Since laboratories are beginning to expand NIPT beyond aneuploidy, participants were asked 
questions regarding the use of NIPT in testing for microdeletion/duplication testing. Participants 
were initially asked if they were familiar with published clinical data about this testing. Nearly a 
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third of participants (35.17%) indicated they agreed while another third (30.51%) indicated they 
disagreed. Only 4.66% strongly agreed. These responses are summarized in Figure 6. The 
responses indicated that overall, participants were less familiar with NIPT 
microdeletion/duplications testing when compared to NIPT aneuploidy testing.  
 
 
Figure 6 Participant Familiarity with NIPT Microdeletion/Duplication Testing 
 
 Participants were also asked to what extent they agreed that microdeletions/duplication 
testing should be offered to patients. Half (50.42%) of participants were neutral and neither 
agreed nor disagreed that it should be offered. Of the participants who believed it should be 
offered, 31.36% agreed and 6.78% strongly agreed. Conversely, 8.47% disagreed and 2.87% 
strongly disagreed. However, a majority (69.92%) of participants indicated that they did not 
provide NIPT microdeletion/duplication testing to all pregnancies, with 20.76% offering such 
testing to only high-risk pregnancies. Only 14 (5.93%) participants were offering this testing to 
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all of their patients. When asked about offering microdeletion/duplication testing in the future, 
70.73% of participants indicated that it was not a test they planned to offer in the next 12 months.   
 When conveying information about microdeletion/duplication testing, the most common 
method for those offering the testing was a discussion between the participants and the patient 
(n=74, 31.35%). The use of genetic counselors was similar to NIPT aneuploidy testing, with 
27.54% speaking face-to-face, and 5.93% utilizing telemedicine. Compared to NIPT aneuploidy, 
slightly more patients were given an informational handout (14.83%).  
 When compared to NIPT aneuploidy testing, there was an overall decrease in confidence 
in interpreting NIPT microdeletion/duplication results. Only 15 (7.25%) participants indicated 
they were very confident. A modest amount indicated they were mostly confident (n=39, 
18.83%) or confident (n=41, 19.81%). More participants indicated they were mostly not 
confident (n=55, 26.54%) or not confident (n=57, 27.54%). A similar trend was found when 
participants indicated their comfort level explaining microdeletion/duplication results to their 
patients. Figure 7 illustrates the breakdown of respondent answers.  
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Figure 7 Comfort Levels of Participants Explaining Microdeletion/Duplication NIPT Results to Patients 
 
 Participants were less likely to offer invasive diagnostic testing given abnormal NIPT 
microdeletion/duplication results than abnormal NIPT aneuploidy results. More than half 
(n=151, 55.51%) indicated that they would offer diagnostic testing, although many (n=97, 
41.1%) indicated that there was not enough information at the present time to recommend it. 
Only 8 (3.39%) participants indicated they would not offer diagnostic testing after abnormal 
NIPT microdeletion/duplication results.  
 Analysis of monogenic disorders is another area in which NIPT testing is expanding. In 
their opinion, most participants (49.15%) neither approved nor disapproved of offering NIPT for 
monogenic disorder analysis. Favorable positions consisted of 14.41% highly approving and 
31.36% mostly approving. Few participants held negative opinions with 4.06% mostly 
disapproving and 0.42% highly disapproving.    
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 Should patients have abnormal monogenic NIPT results, a majority of participants 
(72.03%) indicated they would offer invasive diagnostic testing, while very few (3.39%) 
indicated they would not. Nearly a quarter of participants (24.58%) indicated that it would 
depend on the situation. Some participants elaborated that they would refer patients who received 
abnormal results to other specialists, typically Maternal-Fetal Medicine or genetics, or that they 
would not be offering this testing.  
 When asked to consider if they would offer all three categories of screening with NIPT 
(aneuploidy, microdeletion/duplication, and monogenic disorders) to every patient, most 
participants indicated that they would not and instead preferred to opt-in for expanded testing 
options on a case-by-case basis. However, 25.54% of participants indicated they would want to 
offer the fully expanded NIPT testing options to all their patients. This is depicted in Figure 8.  
 
Figure 8 Opinion Regarding Expanded NIPT for All Patients 
43 
3.4 DISCUSSION  
3.4.1 Knowledge of NIPT  
The initial questions asked were meant to elicit respondents’ knowledge of NIPT. When 
indicating methods by which they had learned about NIPT, the obstetricians indicated that the 
top four were discussion with peers, literature review, discussion with lab representatives, and 
continuing education. This is consistent with previous research of obstetricians and MFM 
specialists showing formal educational activities, literature review, and discussion with peers as 
the most common methods90,91, and with other NIPT providers, including genetic counselors 
whose top methods were discussion with peers, in literature review, discussion with lab 
representatives, and at professional confrences85. As with previous studies, the use of laboratory 
representatives as an education resource could pose an ethical issue.85,90,91 Laboratories have a 
conflict of interest when they serve as both the provider and educator. This is not to say that 
laboratories should not play a role in educating providers, but they should not be the exclusive 
educator. The vast majority (94.89%) indicated the correct timeframe when NIPT could be 
performed, i.e. as early as 10 weeks.  When  a survey of genetic counselors answered with 100% 
accuracy.85 
3.4.2 Opinions of NIPT  
Participants felt that the greatest advantages of NIPT were patient acceptance, availability during 
gestational age, and detection rate. They indicated that coverage by insurance companies 
followed by false positive rates were the greatest limitations. These were the same advantages 
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and limitations of NIPT that genetic counselors indicated, as well.  Where these groups differed 
was in considering the availability of genetic counselors. Genetic counselors (n=23/113, 20.4%) 
viewed their limited availability as more of a limitation compared to the opinions of obstetricians 
(n=26/227,11.5%).85 Genetic counselors may be particularly sensitive to their limited 
availability. Workforce data collected by NSGC highlights the need to increase the number of 
practicing genetic counselors to meet patient demand.95 However, in some instances, 
obstetricians may be confident in their ability to provide patient counseling regarding NIPT even 
given the deficit of training resources and rapid evolution of NIPT. Previous research indicated 
that access to a genetic counselor would be helpful – and even preferred - with abnormal 
results,90 and in this survey, 57.63% indicated they would like access to a genetic counselor 
when results were abnormal. Additionally, 39.4% indicated that they would find pre-test access 
to genetic counselors helpful.  
3.4.3 Alignment of NIPT Practices with Current Guidelines   
This survey was conducted nearly a year after the updated ACOG6 and ACMG71 published their 
updated recommendations which state that all women, not only those at high-risk, should be 
offered all screening options, including NIPT. When specifically asked about offering NIPT to 
low-risk patients, 45.72% indicated that it was not something that they currently do. Of those 
who were offering the testing to low-risk patients, it was still at a lower rate than their high-risk 
patients: 77.83% of participants were offering NIPT to 90-100% of their high-risk patients; 
63.21% were offering to as many low-risk patients.  Of those who were not offering testing to 
their low-risk patients, 90.21% indicated that they had no plans to do so within the next 12 
months. These responses indicated that a significant number of participants appeared to be 
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following an older ACOG committee opinion from 201570, which stated that conventional 
screening remained the best option for general patients, reserving NIPT for high-risk patients. It 
is interesting to note that the participants in this study were all current members of ACOG, and 
hopefully would have access to the updated recommendations.  
Two possible reasons for the observed difference between recommendations and clinical 
practice are limited availability of general population NIPT research and the complications of 
insurance and testing cost to patients. Most of the available literature on NIPT is based on studies 
that have been conducted on high-risk populations. However, recent large-scale studies of NIPT 
in general populations have shown the test to have similar positive predictive values to high-risk 
populations.92,93,96,97 
A practical limitation of NIPT that may deter providers from offering the test is the cost 
of the test for the patient. Other studies have explored this issue. The cost of NIPT varies 
between companies, and reimbursement rates and out-of-pocket costs vary by insurance plan. In 
a 2013 survey of commercial NIPT in the United States, out–of-pocket costs were found to be up 
to $1,700, co-pays up to $235, and direct to insurance bills of up to $2,900.98 A 2016 survey 
found that genetic counselors were concerned about the cost of the test for patients and insurance 
issues.86 Obstetricians may also share these concerns.  
 Additionally, when queried about offering diagnostic testing after abnormal NIPT results, 
4.82% said they did not offer diagnostic testing and 8.56% said that it depends on other factors. 
Recommendations by professional groups, including ACOG, state that all women who received 
abnormal NIPT screening results should be offered confirmatory diagnostic testing. In a previous 
provider knowledge survey, there was a direct correlation between offering confirmatory testing 
and accurately identifying NIPT as a screening, rather than a diagnostic, test.90 Therefore, it is 
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possible that respondents who were not offering confirmatory testing mistakenly viewed NIPT as 
a diagnostic test. 
 Furthermore, none of the guidelines put forth by professional organizations recommend 
NIPT microdeletion/duplication testing and instead maintain that diagnostic testing is the most 
appropriate method for women who are concerned about their risk for conditions caused by 
microdeletions or microduplications. The responses gathered indicated that not all obstetricians 
were following these recommendations; 20.76% were offering this expanded testing to high-risk 
patients and 5.93% were offering it all their patients. While these obstetricians may want to offer 
their patients the most cutting-edge testing available, there are risks to using newer technology 
that have not been extensively researched.  Further exploration of these physicians’ motivations 
and their discussions of expanded testing with patients is warranted 
3.4.4 Future Directions  
Responses showed that most participants currently do not offer microdeletion/duplication to any 
of their patients, and only 20.76% offer it exclusively to high-risk patients. Compared to 
interpretation of aneuploidy test results, confidence in test interpretation and explanation of test 
results to patients decreased for microdeletion/duplications. In regards to confirmatory testing, 
more respondents indicated they would offer invasive testing after abnormal monogenic results 
(72.03%, n=170) than after abnormal microdeletion/duplication results (55.51%, n=131). 
Although NIPT for monogenic disorders is not currently available, 72.03% of participants 
indicated they would offer confirmatory diagnostic testing after an abnormal result. Another 
avenue to explore would be the exact motivation for providers who are offering expanded testing 
to their patients. Open ended survey questions inquiring about motivation should be utilized, 
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including questions asking about influences of laboratory representatives and exploring the many 
facets of expanded testing individually.  
 The majority (72.46%) of participants indicated that they would prefer to opt-in to 
expanded testing options while (27.52%) would want aneuploidy, microdeletions/duplications, 
and monogenic disorders for all patients. None of the previously surveyed genetic counselors 
indicated a preference for the latter option. Instead, each wanted the ability to decide what was 
most appropriate for their patient.85 That most providers want to select the scope of NIPT they 
are offering to their patients implies that they do not feel expanded testing is appropriate for all 
patients.  
3.4.5 Study Limitations  
Invitations to participate were sent to 4770 members and only 238 completed the survey. Given 
the low response rate of 4.98%, it is possible that the participants of this survey do not accurately 
reflect the full population of ACOG members. Another limitation of the survey was that a 
reminder email was not utilized, which may have increased the response rate. As with any 
survey, there is the possibility of selection bias. Participants who were interested in the topic 
and/or confident in their knowledge of NIPT may have been more inclined to participate. 
Conversely, obstetricians who were not confident in their knowledge of NIPT may 
disproportionally represent those who declined to participant. Either of these scenarios would 
lead to an overestimation of participate knowledge and comfort. Additionally, the data for this 
study were based on self-reported responses.  Participants may not have accurately self-assessed 
their knowledge or may have reported answers they believed to be correct rather than an accurate 
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reflection of their clinical practice. In this case, the reported results would overestimate 
participate knowledge and/or comfort.  
3.4.6 Practice Implications  
The majority of obstetricians displayed accurate knowledge of NIPT and confidence in result 
interpretation for aneuploidy test results and their ability to disclose this information to patients, 
but this confidence decreased in regard to expanded NIPT testing that included 
microdeletions/duplication and monogenic disorders. This indicates the need for educational 
materials or CME activities on these newer topics targeted towards providers. Additionally, this 
study revealed a discordance in some obstetricians’ clinical practices compared to recommended 
guidelines put forth by their professional organization. Possible reasons may be that these 
providers are not familiar with the updated recommendations, they may not agree with the 
recommendations, or they may be facing barriers to testing due to insurance complications and 
financial burdens placed on patients. The exact reason for this difference was not evaluated by 
this survey, but should be explored in future research to address this difference.  
3.4.7 Research Recommendations  
As the use of expanded NIPT increases and new professional guidelines regarding it are 
developed, the opinions and clinical practices of healthcare providers should be sought. Further 
surveys of these providers should confirm knowledge of NIPT as a screening test, assess 
awareness of and agreement with current professional guidelines, ask open-ended questions as to 
why they would or would not use expanded NIPT options, and address cost/insurance issues 
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associated with the test. Additional research into the average time it takes for healthcare 
professionals to incorporate new guidelines would also be helpful to assess if the differences in 
recommendation and practice found in this study are in line with the typical adaption timeframe.  
3.5 CONCLUSION  
The introduction of NIPT has brought dramatic changes to the prenatal screening for both 
patients and healthcare practitioners. Even as the test becomes commonplace, both the 
recommendations for clinical implementation and the conditions that can be detected have been 
constantly changing. Now that the recommended testing population has been broadened to 
include all women, it is even more vital for healthcare practitioners to know the benefits and 
limitations of the test, feel confident in their ability to accurately interpret and convey results to 
patients, to understand how NIPT has and will continue to expand, and to be familiar with 
professional guidelines that set standards as to how the test should be implemented. Although 
participants demonstrated adequate familiarity with NIPT testing for aneuploidy, this was not the 
case for microdeletion/duplications or monogenic disorders. Additional information and 
educational support for obstetricians regarding expanded NIPT testing should be developed.   
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4.0  RESEARCH SIGNIFICANCE TO PUBLIC HEALTH AND GENETIC 
COUNSELING 
The goal of public health is promotion and protection of health within a population. This goal is 
achieved through the public health core functions of assessment, policy development and 
assurance.  These core functions encompass and guide the ten essential services of public health, 
including the development of policies in conjunction with stakeholders to implement the most 
effective strategies and assure a competent public health and healthcare workforce.  
Prenatal screening is an intervention offered to all women to identify pregnancies that are 
at risk for birth defects and chromosome abnormalities. Early detection and identification of 
these conditions allows for appropriate alterations of medical management, including changes to 
birthing plans, preparation for surgical interventions immediately after birth, connecting families 
with specialists and services, and possibly time to consider pregnancy termination. While some 
women will choose to undergo prenatal screening and/or testing during their pregnancies and 
other will choose to not undergo any screening, it is important that all women be made aware of 
their options by a knowledgeable medical provider.  
Early prenatal screening methods include sonographic imaging to visualize structural 
defects and maternal serum alpha fetoprotein (MSAFP) levels to indicate the presence of neural 
tube defects. In 1990, the American Public Health Association (APHA) released a policy 
statement acknowledging the multifactorial inheritance of neural tube defects, calling for 
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awareness and education of MSAFP as a screening tool for healthcare providers, and suggesting 
follow-up services including genetic counseling. The statement recognized that appropriate 
guidelines for MSAFP screening had been developed by ACOG and ACMG.99 MSAFP serves an 
example of how polices developed by professional organizations and education of providers 
about testing and its appropriate implementation fall under the purview of public health. 
 The addition of NIPT as a prenatal screening option can be appreciated in a similar 
framework. Professional organizations including ACOG, ACMG, and NSGC have developed 
guidelines for NIPT testing. However, these guidelines, and the practitioners they target, face 
two challenges: the expanding scope of NIPT and the availability of literature supporting 
expanded testing. The constant developments in the field continue to advance faster than the 
literature, which impacts the guidelines. In turn, this can lead to differences in clinical practice as 
even in the presence of developed policy.  
This study revealed some clinical practices that were not congruent with current 
guidelines. The hesitancy of some providers to offer NIPT aneuploidy to all their patients may 
indicate that they feel that there is not enough evidence to support such a recommendation. 
Conversely, providers who were eager to offer expanded NIPT to their patients, against 
recommendations, may believe that the guidelines are not keeping pace with advancements.  
Evaluating providers’ opinions should assist in addressing differences by helping to shape how 
these guidelines are presented, acknowledging provider concerns and leading to informed 
educational supplementation that can be released alongside new guidelines. 
The essential service of ensuring a competent workforce can be achieved through 
provider education. As there are a variety of providers who offer NIPT to patients, understanding 
these providers’ knowledge and confidence in their ability to educate patients about testing, 
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provide adequate informed consent, and correctly interpret test results are important assessments 
which lead to policy development. As fellow providers of NIPT, genetic counselors are 
recognized as valuable assets by some providers, especially regarding interpretation and 
counseling of abnormal NIPT results.90 Additionally, genetic counselors who self-identified as 
working in a public health capacity indicated that 82% of their time was spent educating 
healthcare professionals.100 Therefore, genetic counselors should be included as stakeholders and 
utilized as key resources for the development of provider NIPT education.  
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5.0  PUBLIC HEALTH ESSAY 
5.1 BACKGROUND  
From diagnostic testing like amniocentesis and chorionic villus sampling to maternal serum 
screening methods and imaging via ultrasound, prenatal screening and testing is a rapidly 
evolving field. This trend continues with the introduction of non-invasive prenatal testing 
(NIPT), a screening test that can be completed as early as 10 weeks gestation and looks at cell-
free DNA from the placenta in the mother’s blood. In 2011, aneuploidy NIPT testing was first 
made commercially available, targeted mainly towards women at increased risk to have a child 
with a chromosome disorder.5 In 2013, laboratories started offering expanded NIPT, including 
select microdeletions and microduplications, triploidy, and less common aneuploidies.73 
Currently, NIPT for monogenic disorders is being developed and is likely to be added to 
expanded testing options in the near future. 
 As NIPT continues to change, the professional guidelines and recommendations 
regarding this screening test have also evolved. Previously, aneuploidy NIPT was recommended 
only for women who were considered to be at high risk for aneuploidy compared to the general 
obstetric population.15,70 This changed in 2016 when guidelines from professional organizations 
such as the American College of Obstetricians and Gynecologists (ACOG), the American 
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College of Medical Genetics and Genomics (ACMG), and the National Society of Genetic 
Counseling (NSGC) broadened the recommended NIPT testing population to all women. 6,69,71 
 Now that NIPT is recommended not only to women considered to be at high risk for 
aneuploidies, but to the general obstetric population, it is important to view the testing through a 
public health perspective as it becomes a standard of care. Considering the core functions of 
public health, assessing provider knowledge can identify deficiencies that need to be addressed, 
informing policy development by professional organizations and addressing deficiencies in a 
manner that assures a competent workforce.   
With the rapid uptake of aneuploidy NIPT, the introduction of expanded NIPT options, 
and changes to professional guidelines, it is important to assess providers’ knowledge and 
confidence regarding the screening. In order to assess current practice and knowledge regarding 
NIPT, a survey was developed to assess these across three types of providers: genetic counselors, 
obstetricians, and nurse-midwives.85 Nearly all of the genetic counselors were highly 
knowledgeable about NIPT, confident in interpreting results (99%) and comfortable explaining 
results to patients (99%). However, when it came to microdeletion/duplication NIPT, genetic 
counselors’ confidence in result interpretation and comfort in explaining results to patients 
decreased to 86% and 87%, respectively.85  An even greater decrease between aneuploidy NIPT 
and expanded NIPT was observed in obstetricians as confidence fell from 96.15% to 45.89% and 
comfort dropped from 95.75% to 45.45%. Nurse midwives will be surveyed in the next part of 
this study.  
There are a variety of providers involved in providing NIPT. Regardless of where a 
patient is receiving information about NIPT, it should be consistent across all providers, and 
providers should be confident in their knowledge of NIPT and comfortable discussing the 
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screening with patients. Addressing provider education, with an inclusive, interdisciplinary 
approach, is one avenue to address this issue. This essay proposes utilizing continuing medical 
education (CME), or continuing education (CE), as an intervention through the creation of NIPT 
specific online learning modules and educational material for all providers.  
5.1.1 Prenatal Screening as a Public Health Intervention 
Prenatal screening and testing is currently a standard part of prenatal care. This has evolved over 
time, because when prenatal screening techniques are first introduced they typically are 
developed for a certain population before being expanded to all pregnant women. Additionally, 
as more healthcare providers are involved throughout pregnancy, these screening methods may 
be discussed at several different points during pregnancy and with a variety of healthcare 
professionals. As testing options and providers increase, it is important to consider the role of 
public health in prenatal testing has been examined.  
In a 1999 article published in the American Journal of Preventative Medicine, Dr. Ellen 
Clayton explored public health’s role in newborn screening and prenatal diagnosis given the new 
technologies allowing for such at the time.101 The technology being used for prenatal testing was 
using maternal serum alpha-fetoprotein (MSAFP) as a marker. There was a push to bring 
MSAFP to the general obstetric population as evidenced by the Healthy People 2000’s goal of 
offering the testing to 90% of pregnant women.102 Dr. Clayton discussed how prenatal testing fell 
within a public health framework, including in utero interventions and alterations to the mode or 
location of delivery.101 However, many medical problems indicated prenatally do not have 
corrective medical interventions, meaning that the testing does not fit completely into a public 
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health framework. Regardless, Dr. Clayton emphasized that the accuracy and appropriate 
delivery of prenatal testing techniques was within the purview of public health.101  
 The introduction of NIPT as a new prenatal technology and, now, its general availability 
is analogous to MSAFP. The need for public health assurance in regard to NIPT is two–pronged: 
assuring the accuracy of the test and assuring the competency of the providers offering it. The 
accuracy of the test for detecting common trisomies has been established, and professional 
organizations have changed their recommendations to include NIPT as a screening option for all 
women after additional studies were published regarding the accuracy of the testing in women 
not thought to be at high risk.  As a general obstetric screening option, NIPT falls within the 
purview of public health and, just as with MSAFP, the competency of providers needs to be 
assured. To accomplish that, new programs and educational endeavors to educate providers may 
be useful, and one such intervention is proposed here.  
5.1.2 Educating Prenatal Care Providers 
An article published in the Journal of the American Medical Association, describes traditional 
continuing medical education (CME) as a passive, time-based educational model typically 
consisting of conferences, workshops, or lectures.103 However, computer-aided instruction and 
practice site visits have been described as positive CME interventions.103 The most effective 
CME interventions have several components: a learning needs assessment, peer interaction with 
the opportunity to practice learned skills, and sequenced and multifaceted education activities.103  
There have been a number of studies that have assessed CME, which has consistently 
been shown to be effective when certain interventions are implemented. Three systemic review 
articles assessed the effectiveness of CME spanning from 1975 to 2007.104–106 A number of 
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common themes emerged from these studies. Didactic sessions, conferences, and educational 
materials alone have relatively little impact.104–106 However, by also engaging physicians in 
activities, case discussion, role-play and practice sessions, they are more likely to incorporate 
what they have learned and their behavior is more likely to change.104–106 
As genetics/genomics in medicine continues to rapidly grow, improving genetic 
knowledge among healthcare providers is a necessity.107 Methods by which this can be 
accomplished include updating pre-service education and providing genetics-focused continuing 
education for providers.107 In a 2007 article published in Nature Reviews Genetics, the authors 
outline the importance of genetics, skills and knowledge they believe are essential, and how to 
integrate genetics into provider education.107 Recommendations for integrating genetic education 
for healthcare providers include building connections between research and clinical use, 
developing educational material with representatives from the target audience, and utilizing case-
based, practical examples.108  In a study that aimed to evaluate the implementation of genetics 
curriculum on the skills in genetic diagnosis and counseling of obstetrician-gynecologist 
residents at the George Washington School of Medicine, all 40 residents completed a needs 
assessment and 28 went on to complete the educational intervention.109 The implementation of 
genetic curriculum for obstetrician-gynecologist residents both improved their knowledge, with 
25 of 28 scoring higher on their post-test, and increased their confidence in applying the concepts 
they learned, per debriefing comments. The curriculum of the educational intervention included a 
combination of didactic sessions and an experiential learning case.109 
A 2011 article published in the Journal of Perinatal & Neonatal Nursing by certified 
nurse-midwife Diane Angelini, EdD explored key issues in interdisciplinary and 
interprofessional education.110 It discussed how interprofessional and interdisciplinary 
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continuing education lead to increased professional confidence, promotion of mutual 
understanding between professions, discovery of new resources, an appreciation of other 
professions’ skills, and recognition of overlapping professional functions.110 Establishing 
common knowledge of NIPT across specialties is one step that may lead to more consistent 
prenatal patient care. 
Looking to other specialties to illustrate the incorporation of genetic education, primary 
care physicians (PCPs) provide a useful example. Acknowledging the limited genetics 
knowledge of many PCPs, a perspective article published in Nature Reviews Genetics in 2002 
discussed how to address this knowledge deficit.111 The authors, Wylie Burke of the University 
of Washington’s Department of Medical history and Ethics and Jon Emery of the University of 
Cambridge’s General Practice and Primary Care Research Unit,  suggested methods included the 
promotion of genetic education in medical school curricula, continuing education, and innovative 
approaches for delivering genetic information. The promotion of partnerships between PCPs and 
genetic professionals, especially in joint educational efforts, helped to show areas of overlap 
between the professions and provide opportunities for mutual learning.111 
There is very little research regarding interdisciplinary education for genetic counselors. 
A 2014 study aimed to complete a needs assessment of interdisciplinary education with a focus 
on oncology procedures.112 The proposed interdisciplinary program revolved around 
observations of oncology procedures: colonoscopy, gastroscopy, chemotherapy, and wound care. 
The goal of the program was to increase counselors’ understanding and confidence regarding 
these procedures and in discussing them with both patients and other providers. A total of 56 
registered members of the Australasian Society of Genetic Counsellors (ASGC) who worked in 
cancer genetics completed the survey. More than 95% of participants felt that interdisciplinary 
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observations would benefit their professional development and almost 90% felt the proposed 
program could be implemented in their workplace. These results indicate genetic counselors 
would also benefit from interdisciplinary education.112  
5.1.2.1 Education and Integration of Non-Genetic Screening Methods 
There have been several examples of successful interprofessional educational programs 
developed outside of the field of genetics. In 2015, Shaw-Battista et al. developed a course 
around obstetric ultrasound education for nurses, midwives, physicians, and students.113 The 
course was composed of online learning modules, case-based seminars, and skill labs. Upon 
completion of the course, participants felt that having representatives from different professions 
allowed for collaborative efforts that facilitated learning. Learners also positively cited the varied 
learning formats and activities as beneficial.113  
A second study looked at an educational program developed to increase the knowledge of 
providers involved in newly recommended HIV screening for women during pregnancy.114  
While screening women for HIV during pregnancy to reduce mother to child transmission is now 
a routine part of prenatal and delivery care, it began as a professional recommendation.114 The 
recommendation for the screening by ACOG was implemented in 2004.114  In response to this 
change of professional guidelines that expanded access to screening for HIV, a formal 
educational presentation was developed for all hospital staff who would be involved in the 
screening.114  The multiple presentations were given to accommodate the various disciplines and 
availability of the staff. The presenters were peers of the given audience, in order to take 
advantage of role modeling and peer to peer teaching. Educational materials were also provided, 
including fact sheets for nurses’ stations, information about the test, and suggested wording for 
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orders. Participants’ knowledge increased by more than 35% after the intervention, as evidenced 
by higher scores on the post-test evaluation.114  
5.1.2.2 The Importance of Provider Education About Genetic Screening  
Genetic counselors working in prenatal settings are providers of NIPT and are recognized as 
valuable assets to other providers, especially in regard to interpreting and counseling positive 
NIPT results. However, there are not currently enough genetic counselors to meet demand. There 
are, as of 2016, more than 4,000 board-certified genetic counselors.95 While there has been 
increasing patient volume and provider referrals for genetic counseling services, in part due to 
the expanded recommendations for genetic testing and screening, the number of new counselors 
entering the field is limited by the amount of genetic counseling master’s training programs and 
the capacity of those programs to train students. At the current rate students are entering the 
workforce, less than 2,400 genetic counselors would be added over the next decade, not even 
doubling the size of the workforce.95 While efforts to increase the number of programs and 
current program sizes are being made, other providers integrating genetics into their clinical 
practice to meet patient needs. While more straight-forward prenatal screening is sometime done 
in a patient’s obstetrician’s office, referrals are still made for newer testing and more complex 
cases.  
A 2016 study surveyed 258 general obstetrics-gynecologists and maternal-fetal medicine 
subspecialists regarding education of NIPT, practice patterns, and barriers to using NIPT.115 The 
barriers that were indicated by respondents included lack of time, limited familiarity and 
experience with NIPT, limited staff and resources to assist with counseling, and minimal 
reimbursements for counseling.115 Genetic counselors were acknowledged as an important 
educational resource not only for patients, but for providers, as well.115 However, the shortage of 
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genetic counselors was also noted. Therefore, the study concluded that educational efforts by 
professional organizations should target  a variety of healthcare providers, including nurses and 
nurse-midwives, as NIPT expands from high-risk to the general obstetric population.91  
In the results obtained from our survey, obstetricians indicated that more than half of 
participants learned about NIPT through discussion with peers and literature review. Discussion 
with laboratory representatives and continuing education courses were the next most common 
learning methods. Similarly, more than half of genetic counselors indicated discussion with peers 
and lab representatives, and literature review.85 Additionally, they indicated professional 
conferences and formal education in their training programs.85 
As NIPT continues to rise in popularity among patients and providers, it is vital that 
providers can accurately and comfortably discuss, interpret, and utilize the screening. A 
continuing education course that addresses common genetic knowledge, NIPT specific content, 
and communicating important NIPT concepts to patients may be an effective strategy to increase 
knowledge among a variety of healthcare professionals. Considering the benefits of 
interdisciplinary learning, the course would broadly target the vast array of providers who are 
involved in offering NIPT, instead of targeting each specialty individually. This may also help to 
foster collaboration between healthcare providers and increase awareness about prenatal genetic 
counseling.  
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5.2 RELEVANCE TO PUBLIC HEALTH 
Public health is divided into three core functions: assessment, policy, and assurance. There are 
ten essential services of public health, each of which are associated with one of these core 
functions. The proposed intervention directly addressed several of these essential services.  
One core function of public health is to assess areas where provider knowledge is 
deficient and should be addressed, informing the development of policies and guidelines by 
professional organizations that both oversee continuing education and often serve as sources for 
continuing education content. As previously mentioned, results from our survey assessing 
obstetricians’ knowledge of NIPT revealed deviations from policy put forth by professional 
organizations, which may indicate a need to address knowledge and confidence surrounding 
expanded NIPT.  
If providers are not sufficiently informed or lack confidence in their ability to describe 
and interpret results, the ability for the public to benefit from new advancements is hindered. 
Identifying these areas for improvement, developing plans to facilitate learning and skill 
building, and applying these lessons learned to better anticipate and respond to the needs of 
providers as additional advancements are made in the field, should be central goals of public 
health professionals. 
The goal of the proposed intervention is to increase providers’ knowledge, including the 
benefits and limitations of NIPT, and to increase their comfort and confidence when interpreting 
and reporting results to patients. In this regard, the intervention will directly contribute to the 
essential service of assuring a competent workforce. By including a variety of stakeholders to 
develop and contribute to the learning modules of this intervention, the essential service of 
mobilizing community partnerships to identify and solve health problems is realized.  
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Assessing the effectiveness of the intervention may yield data to allow for novel innovations to 
training healthcare providers about new screening advancements, which incorporates the 
essential service of using research for new insights and innovative solutions to health problems. 
As such, evaluation will be an important part of this intervention from the planning stages 
through implementation.  
5.3 INTERVENTION 
The need for provider education regarding NIPT is evident based on the results of our study and 
previous studies as well as recent changes in professional guidelines. This proposed intervention 
aims to create and implement continuing education modules targeting all prenatal healthcare 
providers. This would be done by gathering invested stakeholders to create online educational 
modules and downloadable material. To assess the effectiveness of the intervention, pre-and 
post-tests will be given to participants to ascertain knowledge of and comfort with NIPT. Figure 
9 displays a logic model as an overview of the intervention.  
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Figure 9 Logic Model of Proposed Intervention 
 
Recorded online videos and an asynchronous method were chosen over live webinars to 
reduce barriers for participants. They will be able to take advantage of each module at a time that 
is most convenient for them. Additionally, pre-recorded content will allow for easy review of 
content, the ability to modify selected portions for updating, and facilitate a consistent, 
professional presentation of material. The addition of comment sections and discussion boards 
allow for peer-to-peer interactions that would be present in a synchronous presentation method. 
5.3.1 Identifying Stakeholders 
There are a wide variety of providers who should be considered as candidate learners, including 
obstetricians, genetic counselors, nurses, nurse-midwives, and maternal fetal medicine 
physicians. Other key stakeholders who would ideally be involved would be professional 
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organizations, accreditation organizations, laboratories, and public health professionals. 
Representatives from each should be involved in contributing to and approving the educational 
material. Additionally, attaining approval of the modules for continuing education credit by 
accrediting organizations would help to incentivize providers to use the material, as well as 
advertise to the appropriate providers. Including the laboratories is important in order to elicit 
information about their testing methods and specifications. Furthermore, the laboratories could 
include a link to the courses on the provider-targeted pages of their websites.  
5.3.2 Initial Project Development 
The project will be initiated with a series of meetings between representatives from each of the 
stakeholder groups. These meetings will address funding, content, and responsibilities. Each 
group will identify how much they can contribute to the project in regards to time, money, and 
other resources. The group will also discuss possible funding options, including grant funding 
and will assign individuals to work on the grant application, if appropriate. Additionally, an 
outline of module topics will be developed. These groups will be asked to also contribute by 
identifying individuals who would be interested and qualified to create the content, serve as the 
video educators, and be the discussion moderators. An approval method will be developed for 
completed modules, post-module quizzes, and the pre- and post-tests to ensure and assess 
learning. 
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5.3.3 Creating the Modules and Resources 
The course and materials would be found on a website and segmented into several modules 
covering different topics. Before starting the modules, an initial assessment will be given as a 
benchmark. Each module will be given in video format and be no more than 10 minutes in 
length, each with an accompanying outline. There will be comment and discussion sections 
associated with each video to allow learners to interact with other peers, as well as ask questions 
about the material. After completing the module, a quiz to assess provider learning will be taken 
before moving on to the next module. 
While the educational materials will be developed by many stakeholders, the following 
are suggestions of components to include: 
• Introduction  
o Genetics Overview: Genes; Chromosomes; Aneuploidy; 
Microdeletions/duplications; Monogenic Disorders  
o Summary of Prenatal Screening and Diagnostic Methods: First Trimester 
Screening; Maternal Serum Screening; Ultrasonography; Chorionic Villus 
Sampling; Amniocentesis 
• NIPT Specific Content 
o How NIPT works; when can it be done; where does fetal DNA originate 
o Possible test results; differences in wording of results; reasons for 
inconclusive/no-call results; interpreting results 
o Understanding laboratory specifications: sensitivity, specificity, and 
positive predictive value 
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o Comparing NIPT to other screening and diagnostic methods: benefits and 
limitations  
o Expanded testing  
o Communicating with patients about NIPT 
o Review the variety of healthcare providers involved with NIPT and their 
roles 
• Professional Guidelines  
In addition to the module, there will be additional educational material made available to 
learners. Quick reference sheets aimed at providers will be created and made available for 
download. Also, materials to assist in discussions of NIPT with patients will be provided. These 
will include infographics on the benefits and limitations of all screening and diagnostic methods.  
5.3.4 Project Goals 
After the creation and approval of the content, the short term (0-12 months) goals of this 
intervention will be to recruit providers to utilize it. Participating laboratories will be asked to 
share a link to the modules on their provider specific NIPT webpages. Professional and 
accreditation organizations will be asked to make their members aware of their course by either 
highlighting it on their respective webpages or emailing their membership bodies. The goal will 
be to have 1,000 healthcare providers start the modules within the first year they are available.  
Upon completing all the modules, learners will take a final assessment that gauges 
knowledge of NIPT and queries their comfort with the testing. The long-term (12-48 months) 
goals of this intervention are for learners increase their score from their pre-test to their post-test. 
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Whether a target increase should be aimed for and what an appropriate increase is would be 
discussed during the stakeholders meeting during the initial project development. During their 
final assessment, at least 90% of learners indicate that they “agree” or “strongly agree” that they 
are comfortable with NIPT. Additional long-term goals include key stakeholders keeping the 
educational material up to date by reassessing for and adding new developments, research, and 
guidelines every six months. Participants will have the option of enrolling in a contact program 
that will email these updates to learners who have already completed the course.  
The discipline of the learners, initial and final evaluation scores, comfort with NIPT, use 
of the fact and information sheets, and opinions on the usefulness of the course will be provided 
to professional organizations and other interested shareholders, as well as shared at professional 
conferences and published. Learners will also be asked to indicate if they felt the course was 
helpful to them, and if they feel it would be beneficial to their peer and other providers. If this 
intervention proves effective, it may be adaptable for provider education of other topics.  
5.3.5 Evaluation of the Effectiveness if the Intervention  
The effectiveness of the intervention will be evaluated by comparing participants’ results from 
their pre-test and post-test. The pre-test determines the baseline of each participants’ general 
NIPT knowledge, as well as knowledge of expanding NIPT. It will also assesses participants’ 
confidence in interpreting NIPT results, and gauge their comfort discussing results with patients. 
These metrics will be re-evaluated on the post-test. Additionally, participants will be asked to 
give a final assessment of the intervention, indicating if they felt it was helpful to them, if they 
believe their colleagues would benefit from participating, and if they would like to enroll to 
receive updates regarding NIPT.  
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5.4 CONCLUSION 
NIPT has become a leading screening method to identify common trisomies and sex 
aneuploidies and is now a screening option for all women during pregnancy, making it a 
screening test that has evolved from being utilized in select individuals to now being offered 
through a model that more closely resembles those used in public health. To fulfill the three-core 
functions of public health regarding NIPT, provider knowledge should be assessed, to assure 
patients can be comfortable with their knowledge and confidence, and policies should be 
developed to address any deficiencies. This study’s survey of obstetricians identified a lack of 
confidence and comfort around expanded NIPT testing.  
 One method to address these deficiencies is through continuing education. Continuing 
education is most effective when interactive through peer-to-peer discussion, utilizing activities 
and practical examples, and taking an interdisciplinary/interprofessional approach. This 
intervention aimed to incorporate all of these elements while allowing for broad availability of 
the content via asynchronous, online access. This allows all providers involved in NIPT, 
regardless of discipline, to participate, learning not only about the content, but their peers’ 
contributions in the multidisciplinary arena of prenatal healthcare.   
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APPENDIX B: SURVEY 
B.1 COVER LETTER  
Dear American Congress of Obstetricians and Gynecologists/American College of Nurse-
Midwives member, 
 
You are being invited to participate in a research study by answering the following survey 
questions about Non-Invasive Prenatal Testing (NIPT). The purpose of this research study is to 
understand current use of NIPT among different medical fields, determine provider 
understanding of NIPT, and explore provider readiness for the increase in prenatal testing 
options offered through NIPT. For that reason, obstetricians and midwives who are members of 
one of the selected professional organizations in the United States will be asked to complete a 
brief questionnaire that is expected to take approximately 15 minutes to complete. The 
questionnaire will include questions regarding demographics, current knowledge of NIPT, and 
readiness for the evolution of NIPT.  
 
There are no foreseeable risks associated with this project, nor are there any direct benefits to 
you. There will not be any payment for participation. All responses are confidential, and results 
will be kept in a password protected document on a password protected computer. The data 
collected in this survey may be shared with investigators conducting similar research; however, 
this information will be shared in a de-identified manner (without identifiers). Your participation 
is voluntary, and you may withdraw from this project at any time.  
 
Due to the nature of this survey, participants must answer all questions in order to submit the 
survey. This study is being conducted by Emily Griffenkranz, a Master’s Degree student in the 
University of Pittsburgh Genetic Counseling Program, who can be reached at emg88@pitt.edu, if 
you have any questions. 
 
This study has been reviewed and approved by the University of Pittsburgh Institutional Review 
Board (IRB#PRO16100624). 
 
Please use the follow anonymous link to enter the survey: 
https://pitt.co1.qualtrics.com/SE/?SID=SV_3Fa58nPHxXg3yjr 
 
Thank you in advance for your time,  
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Emily Griffenkranz 
Department of Human Genetics 
University of Pittsburgh 
 
B.2 SURVEY 
Provider Knowledge of Non-Invasive Prenatal Testing (NIPT) 
                       
You are being invited to participate in a research study by answering the following 
survey questions about Non-Invasive Prenatal Testing (NIPT). The purpose of this research 
study is to understand current use of NIPT among different medical fields, determine provider 
understanding of NIPT, and explore provider readiness for the increase in prenatal testing 
options offered through NIPT. For that reason, obstetricians and midwives who are members of 
one of the selected professional organizations in the United States will be asked to complete a 
brief questionnaire that is expected to take approximately 15 minutes to complete. The 
questionnaire will include questions regarding demographics, current knowledge of NIPT, and 
readiness for the evolution of NIPT. There are no foreseeable risks associated with this project, 
nor are there any direct benefits to you. There will not be any payment for participation. All 
responses are confidential, and results will be kept in a password protected document on a 
password protected computer. Your participation is voluntary, and you may withdraw from this 
project at any time. Due to the nature of this survey, participants must answer all questions in 
order to submit the survey. This study is being conducted by Emily Griffenkranz, a Master’s 
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Degree student in the University of Pittsburgh Genetic Counseling Program, who can be reached 
at emg88@pitt.edu, if you have any questions.     
 
Emily Griffenkranz  
Department of Human Genetics 
University of Pittsburgh 
 
Non-Invasive Prenatal Testing (NIPT) is a new technology that is rapidly evolving. The 
methodology involves the collection of a blood sample from the mother for analysis of cell-free 
fetal DNA in maternal plasma. Its most common and current utilization is the quantification of 
cell-free fetal DNA from chromosomes 13, 18, and 21 to detect the presence of an abnormal 
number of chromosomes in a cell, referred to as aneuploidy. 
 
1. To what extent do you agree or disagree with the following statement: I am familiar with 
published NIPT clinical data. 
[ ] Strongly Disagree  
[ ] Disagree  
[ ] Neither Agree nor Disagree  
[ ] Agree  
[ ] Strongly Agree  
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2. How did you learn about NIPT? (Check all that apply.) 
[ ] I have not learned about NIPT  
[ ] Formal education  
[ ] Continuing education course  
[ ] Discussion with lab representative  
[ ] Discussion with peers  
[ ] Lab company advertisements  
[ ] Literature review  
[ ] Online researching  
[ ] Conference  
[ ] Other  ____________________ 
 
3. NIPT for aneuploidy can be conducted at what gestational age? 
[ ] Anytime  
[ ] As early as 10 weeks  
[ ] As early as 15 weeks  
[ ] As early as 20 weeks  
[ ] I don't know  
 
4. Which of the following criteria do you use in your practice to determine whether a patient is 
at high-risk for carrying an aneuploid pregnancy? (Check all that apply.) 
[ ] Maternal age  
[ ] An abnormal first trimester screening result  
[ ] An abnormal maternal serum screening result  
[ ] Abnormal ultrasound finding  
[ ] Family history of aneuploidy  
[ ] Previous pregnancy with aneuploidy  
[ ] Other ____________________ 
 
5. Do you offer NIPT to high-risk pregnancies? 
[ ] Yes  
[ ] No  ____________________ 
 
6. If yes, what percent of high-risk patients do you offer/refer NIPT? 
[ ] 90-100%  
[ ] 75-90%  
[ ] 50-75%  
[ ] 25-50%  
[ ] 10-25%  
[ ] <10% 
[ ] None 
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7. If not, do you plan to offer NIPT to high-risk pregnancies in the next 12 months? 
[ ] Yes  
[ ] No  
 
8. Do you offer NIPT to low-risk pregnancies with no significant risk factors for aneuploidy? 
[ ] Yes  
[ ] No  
 
9. If not, do you plan to offer NIPT to low-risk pregnancies with no significant risk factors for 
aneuploidy in the next 12 months? 
[ ] Yes  
[ ] No  
 
10. What percent of low-risk patients do you offer/refer for NIPT? 
[ ] 90-100%  
[ ] 75-90%  
[ ] 50-75%  
[ ] 25-50%  
[ ] 10-25%  
[ ] <10% 
[ ] None  
 
11. To what extent do the following factors influence your decision to offer NIPT? 
 No Influence Slight Influence Strong Influence 
Abnormal serum screen result    
Advanced maternal age    
Prior fetus affected with aneuploidy    
Increased nuchal translucency    
Ultrasound markers associated with 
increased risk of aneuploidy  
   
Patient presenting late in gestation 
and past optimal time for screening 
procedures 
   
Family history of aneuploidy    
Patient with no indication requested 
testing 
   
Other ______________________    
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12. Do you find the following to be advantages or limitations when ordering NIPT as compared 
to other screening tests such as first trimester screening and quad screening? 
 Advantage Neutral Limitation N/A 
Recommended by scientific studies     
Recommended by professional societies     
Associated risk to pregnancy     
My history of experience with the test     
Coverage by insurance companies     
Detection rate     
Patient acceptance     
Patient Anxiety     
Risk associated with follow-up invasive testing     
False positives     
Availability during gestational age     
Availability of genetic counseling     
Other __________________     
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13. How is information about NIPT for aneuploidy provided to your patients prior to testing? 
(Check all that apply.) 
[ ] Patients speak face-to-face with a genetic counselor  
[ ] Patients speak with a genetic counselor through telemedicine  
[ ] I discuss NIPT with the patient  
[ ] Patients speak to a health care provider other than a genetic counselor in my office  
[ ] Patients speak to a health care provider other than a genetic counselor who is not part of 
my office  
[ ] Patients read an information handout first  
[ ] I do not order this test  
[ ] Other  ____________________ 
 
14. How confident are you interpreting patient NIPT results? 
[ ] Not confident  
[ ] Mostly not confident  
[ ] Confident  
[ ] Mostly confident  
[ ] Very confident  
[ ] N/A  
 
15. How comfortable are you explaining NIPT results to your patients? 
[ ] Not comfortable  
[ ] Mostly not comfortable  
[ ] Comfortable  
[ ] Mostly comfortable  
[ ] Very comfortable  
[ ] N/A  
 
16. If a patient has an abnormal NIPT result, do you offer invasive diagnostic testing 
(amniocentesis or chorionic villus sampling)? 
[ ] Yes  
[ ] No  
[ ] It depends  ____________________ 
 
17. When would you find access to a genetic counselor helpful during the process of ordering 
NIPT? 
[ ] Before offering NIPT  
[ ] After results come back and are abnormal  
[ ] Only if results are abnormal  
[ ] I do not offer genetic counseling  
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Recent research has contributed to the development of expanded testing opportunities 
through NIPT. This testing includes aneuploidy detection involving additional chromosomes as 
well as assessment of the presence of microdeletions and microduplications, which may be 
associated with certain genetic conditions. By definition, a microdeletion is the loss of a small 
fragment of a chromosome that involves several contiguous genes. A microduplication is a gain 
of a small fragment of a chromosome. Microdeletions and microduplications are typically too 
small to be detected by conventional cytogenetic methods such as light microscopy using high 
resolution karyotyping. Detection for microdeletions and microduplications are traditionally 
done by procedures such as fluorescence in-situ hybridization (FISH) or microarray analysis.       
In the future, NIPT may also have the potential to analyze the presence of monogenic 
disorders. Monogenic disorders such as cystic fibrosis are known to be caused by mutations in a 
specific gene. Expansion of NIPT to include analysis of monogenic disorders can allow for 
recognition of these conditions in a fetus early in pregnancy.   
18. To what extent do you agree or disagree with the following statement: I am familiar with 
published clinical data regarding microdeletions/microduplications within the context of 
NIPT. 
[ ] Strongly disagree  
[ ] Disagree  
[ ] Neither Agree nor Disagree  
[ ] Agree  
[ ] Strongly Agree  
 
19. To what extent do you agree or disagree with the following statement: 
microdeletion/microduplication analysis should be offered in NIPT. 
[ ] Strongly disagree  
[ ] Disagree  
[ ] Neither Agree nor Disagree  
[ ] Agree  
[ ] Strongly Agree  
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20. Do you offer microdeletion/microduplication NIPT to all pregnancies? 
[ ] Yes  
[ ] No  
[ ] Only to high risk pregnancies  
[ ] Other ____________________ 
 
21. If not, do you plan to offer NIPT with microdeletion/microduplication in the next 12 
months?  
[ ] Yes  
[ ] No  
 
22. Which of the following criteria do you use to determine that a patient is at increased risk for 
having a fetus with a microdeletion/microduplication? (Check all that apply.) 
[ ] Family with a known microdeletion/microduplication disorder  
[ ] Prior fetus affected with a microdeletion/microduplication disorder  
[ ] Ultrasound finding  
[ ] I don't know  
[ ] Other  ____________________ 
 
23. How is information about NIPT with microdeletion/microduplication analysis provided to 
your patients prior to testing? (Check all that apply.) 
[ ] Patients speak face-to-face with a genetic counselor  
[ ] Patients speak with a genetic counselor through telemedicine  
[ ] I discuss NIPT with the patient  
[ ] Patients speak to a health care provider other than a genetic counselor in my office  
[ ] Patients speak with a health care provider other than a genetic counselor who is not part of 
my office  
[ ] Patients read an information handout first  
[ ] I do not order this test  
[ ] Other  ____________________ 
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24. How confident are you interpreting patient microdeletion/microduplication NIPT results? 
[ ] Not confident  
[ ] Mostly not confident  
[ ] Confident  
[ ] Mostly confident  
[ ] Very confident  
[ ] N/A  
 
25. How comfortable are you explaining microdeletion/microduplication NIPT results to your 
patients? 
[ ] Not comfortable  
[ ] Mostly not comfortable  
[ ] Comfortable  
[ ] Mostly comfortable  
[ ] Very comfortable  
[ ] N/A  
 
26. If a patient has an abnormal microdeletion/microduplication NIPT result, do you offer 
invasive diagnostic testing (amniocentesis or chorionic villus sampling)? 
[ ] Yes  
[ ] No  
[ ] Not enough information at the present time  
 
27. What is your opinion about offering analysis of monogenic disorders in NIPT? 
[ ] Highly disapprove  
[ ] Mostly disapprove  
[ ] Neither approve nor disapprove  
[ ] Mostly approve  
[ ] Highly approve  
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28. Which of the following criteria would you use to determine that a fetus is at an increased risk 
for monogenic disorders? (Check all that apply.) 
[ ] Family history of a known monogenic disorder  
[ ] Family where the mother or father is known to be a carrier for the disorder  
[ ] Family where the mother or father is suspected to be a carrier for the disorder based on 
family history  
[ ] Prior fetus affected with a monogenic disorder  
[ ] Ultrasound finding  
[ ] Would offer to all pregnancies  
[ ] I don't know  
[ ] Other  ____________________ 
 
29. If the patient has an abnormal NIPT result regarding a monogenic disorder, would you offer 
invasive diagnostic testing (amniocentesis or chorionic villus sampling)? 
[ ] Yes (1) 
[ ] No (2) 
[ ] It depends (3) ____________________ 
 
30. In your opinion, would you want all NIPT labs to offer screening only for the 3 categories 
(aneuploidy, microdeletion/microduplication, and monogenic disorders) without option for 
fewer categories? 
[ ] Yes, I would only want labs to offer all 3 categories every time for every patient  
[ ] No, I would want to be able to choose the target category(ies) that are most pertinent to 
my patient; testing performed on a case by case basis with additional options (beyond 
aneuploidy testing) offered on an opt-in basis  
 
Demographics 
31. What is your field of specialty? 
[ ] Certified Nurse Midwife  
[ ] Certified Midwife  
[ ] Genetic Counselor  
[ ] Obstetrics & Gynecology  
[ ] Other  ____________________ 
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32. Do you have a sub-specialty? 
[ ] Yes  ____________________ 
[ ] No  
 
33. What is your primary work setting? 
[ ] Academic  
[ ] Private Practice  
[ ] Hospital Based  
[ ] Lab  
 
34. How many years have you been practicing 
[ ] 0-2 years  
[ ] 2-5 years  
[ ] 5-10 years  
[ ] 10+ years  
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APPENDIX C: ADDITIONAL RESULTS 
These are the remaining findings elicited from the survey that were not included in the 
manuscript.   
Participants were asked to select all criteria used in their practice to determine a high-risk 
pregnancy. A detailed graph of responses is shown in Figure 10. A majority of participants used 
maternal age (n=233, 98.73%), ultrasound anomalies (n=220, 93.22%), and previous pregnancy 
with aneuploidy (n=217, 91.95%) as determinants of a high-risk pregnancy. Many also indicated 
an abnormal maternal serum screening result (n=207, 87.71%) and an abnormal first trimester 
screening result (n=199, 84.32%) as meeting their high-risk criteria. More than half (n=165, 
69.92%) used family history of aneuploidy as a determining factor. Thirteen (5.51%) participants 
selected other as a response. When these participants elaborated further in an open-ended text 
question, ten indicated that they were offering NIPT either to all patients or at patients’ request.  
Participants were queried about the extent to which several factors influenced their 
decision to offer NIPT to patients. The strong influences were abnormal serum screening 
(84.62%, n=198), advanced maternal age (92.70%, n=216), prior fetus affected with aneuploidy 
(89.7%, n=209), increased nuchal translucency (88.41%, n=206), and ultrasound markers 
associated with increased risk of aneuploidy (89.74%, n=210). A family history of aneuploidy 
was indicated as a strong influence (48.26%, n=111) for some and a slight influence (42.68%, 
n=98) in others. Patients presenting later in gestation were mostly a slight influence (42.49%, 
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n=99) or no influence (40.39%, n=94). Participants were almost evenly divided regarding 
patients with no indication who requested testing: 30% (n=67) strong influence, 38.96% (n=90) 
slight influence, and 32.03% (n=74) no influence. Other factors mentioned by participants 
included insurance coverage and cost of testing, lack of first trimester screening in their 
practicing area, and practice of offering NIPT to all patients.   
 
Figure 10 Criteria for Determining Pregnancies at High-Risk for Aneuploidy 
 
A majority of participants indicated that a known family history of a 
microdeletion/duplication disorder (96.76%, n=179) and a prior fetus affected with a 
microdeletion/duplication disorder (96.22%, n=178) were criteria used to identify patients at an 
increased risk. Ultrasound as a criterion was indicated by 55.14% (n=102) of participants. The 
remaining participants’ comments to an open ended question indicated that they did not use a lab 
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with this kind of expanded testing, that it was not a test that they offered to any patients, or that it 
was provided to all patients. 
The most agreed upon criteria participants would use for determining increased risk for a 
monogenic disorder were a known family history of the disorder (n=181, 94.27%), family where 
a parent is a known carrier (n=182, 94.79%), and a prior affected fetus (n=181, 94.27%). Many 
(n=148, 77.08%) would use suspected parental carrier status and ultrasound findings (n=120, 
62.5%) as criteria. A minority (n=16, 8.33%) would offer the expanded testing to all 
pregnancies. 
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